1
|
Bruner E, Holloway R, Baab KL, Rogers MJ, Semaw S. The endocast from Dana Aoule North (DAN5/P1): A 1.5 million year-old human braincase from Gona, Afar, Ethiopia. Am J Biol Anthropol 2023; 181:206-215. [PMID: 36810873 DOI: 10.1002/ajpa.24717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/19/2021] [Revised: 12/09/2022] [Accepted: 02/06/2023] [Indexed: 02/24/2023]
Abstract
The nearly complete cranium DAN5/P1 was found at Gona (Afar, Ethiopia), dated to 1.5-1.6 Ma, and assigned to the species Homo erectus. Its size is, nonetheless, particularly small for the known range of variation of this taxon, and the cranial capacity has been estimated as 598 cc. In this study, we analyzed a reconstruction of its endocranial cast, to investigate its paleoneurological features. The main anatomical traits of the endocast were described, and its morphology was compared with other fossil and modern human samples. The endocast shows most of the traits associated with less encephalized human taxa, like narrow frontal lobes and a simple meningeal vascular network with posterior parietal branches. The parietal region is relatively tall and rounded, although not especially large. Based on our set of measures, the general endocranial proportions are within the range of fossils included in the species Homo habilis or in the genus Australopithecus. Similarities with the genus Homo include a more posterior position of the frontal lobe relative to the cranial bones, and the general endocranial length and width when size is taken into account. This new specimen extends the known brain size variability of Homo ergaster/erectus, while suggesting that differences in gross brain proportions among early human species, or even between early humans and australopiths, were absent or subtle.
Collapse
Affiliation(s)
- Emiliano Bruner
- Programa de Paleobiología, Centro Nacional de Investigación sobre la Evolución Humana, Burgos, Spain
| | - Ralph Holloway
- Department of Anthropology, Columbia University, New York, New York, USA
| | - Karen L Baab
- Department of Anatomy, Midwestern University, Glendale, Arizona, USA
| | - Michael J Rogers
- Department of Anthropology, Southern Connecticut State University, New Haven, Connecticut, USA
| | - Sileshi Semaw
- Programa de Arqueología, Centro Nacional de Investigación sobre la Evolución Humana, Burgos, Spain.,Stone Age Institute, Gosport, Indiana, USA
| |
Collapse
|
2
|
Munoz MA, Skinner OP, Masle-Farquhar E, Jurczyluk J, Xiao Y, Fletcher EK, Kristianto E, Hodson MP, O'Donoghue SI, Kaur S, Brink R, Zahra DG, Deenick EK, Perry KA, Robertson AA, Mehr S, Hissaria P, Mulders-Manders CM, Simon A, Rogers MJ. Increased core body temperature exacerbates defective protein prenylation in mouse models of mevalonate kinase deficiency. J Clin Invest 2022; 132:160929. [PMID: 36189795 PMCID: PMC9525117 DOI: 10.1172/jci160929] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2022] [Accepted: 08/02/2022] [Indexed: 11/17/2022] Open
Abstract
Mevalonate kinase deficiency (MKD) is characterized by recurrent fevers and flares of systemic inflammation, caused by biallelic loss-of-function mutations in MVK. The underlying disease mechanisms and triggers of inflammatory flares are poorly understood because of the lack of in vivo models. We describe genetically modified mice bearing the hypomorphic mutation p.Val377Ile (the commonest variant in patients with MKD) and amorphic, frameshift mutations in Mvk. Compound heterozygous mice recapitulated the characteristic biochemical phenotype of MKD, with increased plasma mevalonic acid and clear buildup of unprenylated GTPases in PBMCs, splenocytes, and bone marrow. The inflammatory response to LPS was enhanced in compound heterozygous mice and treatment with the NLRP3 inflammasome inhibitor MCC950 prevented the elevation of circulating IL-1β, thus identifying a potential inflammasome target for future therapeutic approaches. Furthermore, lines of mice with a range of deficiencies in mevalonate kinase and abnormal prenylation mirrored the genotype-phenotype relationship in human MKD. Importantly, these mice allowed the determination of a threshold level of residual enzyme activity, below which protein prenylation is impaired. Elevated temperature dramatically but reversibly exacerbated the deficit in the mevalonate pathway and the defective prenylation in vitro and in vivo, highlighting increased body temperature as a likely trigger of inflammatory flares.
Collapse
Affiliation(s)
- Marcia A Munoz
- Garvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia
| | - Oliver P Skinner
- Garvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia
| | - Etienne Masle-Farquhar
- Garvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia
| | - Julie Jurczyluk
- Garvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia
| | - Ya Xiao
- Garvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia
| | - Emma K Fletcher
- Garvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia
| | - Esther Kristianto
- Victor Chang Cardiac Innovation Centre, Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia
| | - Mark P Hodson
- School of Pharmacy, University of Queensland, Woolloongabba, Queensland, Australia
| | - Seán I O'Donoghue
- Garvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia
| | - Sandeep Kaur
- Garvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia
| | - Robert Brink
- Garvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia
| | - David G Zahra
- Garvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia
| | - Elissa K Deenick
- Garvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia
| | - Kristen A Perry
- Garvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia
| | - Avril Ab Robertson
- School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Queensland, Australia
| | - Sam Mehr
- Royal Children's Hospital, Melbourne, Victoria, Australia
| | - Pravin Hissaria
- Royal Adelaide Hospital, SA Pathology and University of Adelaide, Adelaide, South Australia, Australia
| | - Catharina M Mulders-Manders
- Department of Internal Medicine, Radboudumc Expertise Centre for Immunodeficiency and Autoinflammation, Radboud University Medical Centre, Nijmegen, Netherlands
| | - Anna Simon
- Department of Internal Medicine, Radboudumc Expertise Centre for Immunodeficiency and Autoinflammation, Radboud University Medical Centre, Nijmegen, Netherlands
| | - Michael J Rogers
- Garvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia
| |
Collapse
|
3
|
Munoz MA, Fletcher EK, Skinner OP, Jurczyluk J, Kristianto E, Hodson MP, Sun S, Ebetino FH, Croucher DR, Hansbro PM, Center JR, Rogers MJ. Bisphosphonate drugs have actions in the lung and inhibit the mevalonate pathway in alveolar macrophages. eLife 2021; 10:e72430. [PMID: 34967731 PMCID: PMC8718110 DOI: 10.7554/elife.72430] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2021] [Accepted: 12/19/2021] [Indexed: 01/29/2023] Open
Abstract
Bisphosphonates drugs target the skeleton and are used globally for the treatment of common bone disorders. Nitrogen-containing bisphosphonates act by inhibiting the mevalonate pathway in bone-resorbing osteoclasts but, surprisingly, also appear to reduce the risk of death from pneumonia. We overturn the long-held belief that these drugs act only in the skeleton and show that a fluorescently labelled bisphosphonate is internalised by alveolar macrophages and large peritoneal macrophages in vivo. Furthermore, a single dose of a nitrogen-containing bisphosphonate (zoledronic acid) in mice was sufficient to inhibit the mevalonate pathway in tissue-resident macrophages, causing the build-up of a mevalonate metabolite and preventing protein prenylation. Importantly, one dose of bisphosphonate enhanced the immune response to bacterial endotoxin in the lung and increased the level of cytokines and chemokines in bronchoalveolar fluid. These studies suggest that bisphosphonates, as well as preventing bone loss, may boost immune responses to infection in the lung and provide a mechanistic basis to fully examine the potential of bisphosphonates to help combat respiratory infections that cause pneumonia.
Collapse
Affiliation(s)
- Marcia A Munoz
- Garvan Institute of Medical Research and St Vincent’s Clinical School, UNSW SydneySydneyAustralia
| | - Emma K Fletcher
- Garvan Institute of Medical Research and St Vincent’s Clinical School, UNSW SydneySydneyAustralia
| | - Oliver P Skinner
- Garvan Institute of Medical Research and St Vincent’s Clinical School, UNSW SydneySydneyAustralia
| | - Julie Jurczyluk
- Garvan Institute of Medical Research and St Vincent’s Clinical School, UNSW SydneySydneyAustralia
| | - Esther Kristianto
- Victor Chang Cardiac Research Institute Innovation CentreSydneyAustralia
| | - Mark P Hodson
- Victor Chang Cardiac Research Institute Innovation CentreSydneyAustralia
- School of Pharmacy, University of QueenslandWoolloongabbaAustralia
| | - Shuting Sun
- BioVincPasadenaUnited States
- University of Southern CaliforniaLos AngelesUnited States
| | | | - David R Croucher
- Garvan Institute of Medical Research and St Vincent’s Clinical School, UNSW SydneySydneyAustralia
| | - Philip M Hansbro
- Centre for Inflammation, Centenary Institute and University of Technology SydneySydneyAustralia
| | - Jacqueline R Center
- Garvan Institute of Medical Research and St Vincent’s Clinical School, UNSW SydneySydneyAustralia
| | - Michael J Rogers
- Garvan Institute of Medical Research and St Vincent’s Clinical School, UNSW SydneySydneyAustralia
| |
Collapse
|
4
|
McDonald MM, Khoo WH, Ng PY, Xiao Y, Zamerli J, Thatcher P, Kyaw W, Pathmanandavel K, Grootveld AK, Moran I, Butt D, Nguyen A, Corr A, Warren S, Biro M, Butterfield NC, Guilfoyle SE, Komla-Ebri D, Dack MR, Dewhurst HF, Logan JG, Li Y, Mohanty ST, Byrne N, Terry RL, Simic MK, Chai R, Quinn JM, Youlten SE, Pettitt JA, Abi-Hanna D, Jain R, Weninger W, Lundberg M, Sun S, Ebetino FH, Timpson P, Lee WM, Baldock PA, Rogers MJ, Brink R, Williams GR, Bassett JD, Kemp JP, Pavlos NJ, Croucher PI, Phan TG. Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell 2021; 184:1940. [PMID: 33798441 PMCID: PMC8024244 DOI: 10.1016/j.cell.2021.03.010] [Citation(s) in RCA: 47] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
5
|
McDonald MM, Khoo WH, Ng PY, Xiao Y, Zamerli J, Thatcher P, Kyaw W, Pathmanandavel K, Grootveld AK, Moran I, Butt D, Nguyen A, Corr A, Warren S, Biro M, Butterfield NC, Guilfoyle SE, Komla-Ebri D, Dack MRG, Dewhurst HF, Logan JG, Li Y, Mohanty ST, Byrne N, Terry RL, Simic MK, Chai R, Quinn JMW, Youlten SE, Pettitt JA, Abi-Hanna D, Jain R, Weninger W, Lundberg M, Sun S, Ebetino FH, Timpson P, Lee WM, Baldock PA, Rogers MJ, Brink R, Williams GR, Bassett JHD, Kemp JP, Pavlos NJ, Croucher PI, Phan TG. Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell 2021; 184:1330-1347.e13. [PMID: 33636130 PMCID: PMC7938889 DOI: 10.1016/j.cell.2021.02.002] [Citation(s) in RCA: 153] [Impact Index Per Article: 51.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2019] [Revised: 11/20/2020] [Accepted: 02/01/2021] [Indexed: 02/02/2023]
Abstract
Osteoclasts are large multinucleated bone-resorbing cells formed by the fusion of monocyte/macrophage-derived precursors that are thought to undergo apoptosis once resorption is complete. Here, by intravital imaging, we reveal that RANKL-stimulated osteoclasts have an alternative cell fate in which they fission into daughter cells called osteomorphs. Inhibiting RANKL blocked this cellular recycling and resulted in osteomorph accumulation. Single-cell RNA sequencing showed that osteomorphs are transcriptionally distinct from osteoclasts and macrophages and express a number of non-canonical osteoclast genes that are associated with structural and functional bone phenotypes when deleted in mice. Furthermore, genetic variation in human orthologs of osteomorph genes causes monogenic skeletal disorders and associates with bone mineral density, a polygenetic skeletal trait. Thus, osteoclasts recycle via osteomorphs, a cell type involved in the regulation of bone resorption that may be targeted for the treatment of skeletal diseases.
Collapse
Affiliation(s)
- Michelle M McDonald
- Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, NSW, Australia
| | - Weng Hua Khoo
- Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, NSW, Australia
| | - Pei Ying Ng
- Bone Biology & Disease Laboratory, School of Biomedical Sciences, University of Western Australia, Nedlands, WA, Australia
| | - Ya Xiao
- Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia
| | - Jad Zamerli
- Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia
| | - Peter Thatcher
- Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia
| | - Wunna Kyaw
- Immunology Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia
| | | | - Abigail K Grootveld
- Immunology Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia
| | - Imogen Moran
- Immunology Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia
| | - Danyal Butt
- Immunology Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia
| | - Akira Nguyen
- Immunology Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia
| | - Alexander Corr
- Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, NSW, Australia
| | - Sean Warren
- Cancer, Garvan Institute of Medical Research, Sydney, NSW, Australia
| | - Maté Biro
- EMBL Australia, Single Molecule Science Node, School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia
| | - Natalie C Butterfield
- Molecular Endocrinology Laboratory, Department of Metabolism, Digestion & Reproduction, Imperial College London, London, UK
| | - Siobhan E Guilfoyle
- Molecular Endocrinology Laboratory, Department of Metabolism, Digestion & Reproduction, Imperial College London, London, UK
| | - Davide Komla-Ebri
- Molecular Endocrinology Laboratory, Department of Metabolism, Digestion & Reproduction, Imperial College London, London, UK
| | - Michael R G Dack
- Molecular Endocrinology Laboratory, Department of Metabolism, Digestion & Reproduction, Imperial College London, London, UK
| | - Hannah F Dewhurst
- Molecular Endocrinology Laboratory, Department of Metabolism, Digestion & Reproduction, Imperial College London, London, UK
| | - John G Logan
- Molecular Endocrinology Laboratory, Department of Metabolism, Digestion & Reproduction, Imperial College London, London, UK
| | - Yongxiao Li
- John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia
| | - Sindhu T Mohanty
- Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, NSW, Australia
| | - Niall Byrne
- Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, NSW, Australia
| | - Rachael L Terry
- Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, NSW, Australia
| | - Marija K Simic
- Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, NSW, Australia
| | - Ryan Chai
- Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia
| | - Julian M W Quinn
- Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, NSW, Australia
| | - Scott E Youlten
- Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia
| | - Jessica A Pettitt
- Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia
| | - David Abi-Hanna
- Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, NSW, Australia
| | - Rohit Jain
- Immune Imaging Program, Centenary Institute, Sydney, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia
| | - Wolfgang Weninger
- Immune Imaging Program, Centenary Institute, Sydney, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia; Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - Mischa Lundberg
- The University of Queensland Diamantina Institute, University of Queensland, Woolloongabba, QLD, Australia; Transformational Bioinformatics, Commonwealth Scientific and Industrial Research Organisation, Sydney, NSW, Australia
| | | | | | - Paul Timpson
- Cancer, Garvan Institute of Medical Research, Sydney, NSW, Australia
| | - Woei Ming Lee
- John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia
| | - Paul A Baldock
- Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, NSW, Australia
| | - Michael J Rogers
- Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, NSW, Australia
| | - Robert Brink
- St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, NSW, Australia; Immunology Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia
| | - Graham R Williams
- Molecular Endocrinology Laboratory, Department of Metabolism, Digestion & Reproduction, Imperial College London, London, UK
| | - J H Duncan Bassett
- Molecular Endocrinology Laboratory, Department of Metabolism, Digestion & Reproduction, Imperial College London, London, UK
| | - John P Kemp
- The University of Queensland Diamantina Institute, University of Queensland, Woolloongabba, QLD, Australia; Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, UK
| | - Nathan J Pavlos
- Bone Biology & Disease Laboratory, School of Biomedical Sciences, University of Western Australia, Nedlands, WA, Australia
| | - Peter I Croucher
- Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, NSW, Australia.
| | - Tri Giang Phan
- St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, NSW, Australia; Immunology Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia.
| |
Collapse
|
6
|
Matheson LM, Pitson G, Yap CH, Singh M, Collins I, Campbell P, Patrick A, Rogers MJ. Measuring the quality of cancer care in the Barwon South Western region, Victoria, Australia. Int J Qual Health Care 2021; 33:5983668. [PMID: 33196785 DOI: 10.1093/intqhc/mzaa145] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 09/29/2020] [Accepted: 10/29/2020] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVE The implementation of clinical quality indicators for monitoring cancer care in regional, rural and remote areas. DESIGN Retrospective data from a population-based Clinical Quality Registry for lung, colorectal and breast cancers. SETTING All major health services in the Barwon South Western region, Victoria, Australia. PARTICIPANTS All patients who were diagnosed with cancer and who presented to a health service. INTERVENTION(S) Clinical subgroups to review variations. MAIN OUTCOME MEASURES(S) Clinical quality indicators for lung, colorectal and breast cancers. RESULTS Clinical indicators included the following: discussion at multidisciplinary meetings, the timeliness of care provided and the type of care for different stages of the disease and survival outcomes. Many of the derived clinical indicator targets were reached. However, variations led to an improvement in the tumour stage being recorded in the medical record; an improved awareness of the need for adjuvant chemotherapy for colorectal cancer; a reduction in time to treatment for lung cancer and a reduced time to surgery for breast cancer, and the 30-day mortality post-treatment for all of the tumour streams was highlighted. CONCLUSIONS Clinical quality indicators allow for valuable insights into patterns of care. These indicators are easily reproduced and may be of use to other cancer centres and health services.
Collapse
Affiliation(s)
- L M Matheson
- Barwon South Western Regional Integrated Cancer Services, 70 Swanston Street, Geelong, VIC 3220, Australia
| | - G Pitson
- Andrew Love Cancer Centre, 70 Swanston Street, Geelong, VIC 3220, Australia
| | - C H Yap
- Cardiothoracic Surgery, University Hospital Geelong, Geelong, VIC 3220, Australia.,Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
| | - M Singh
- Andrew Love Cancer Centre, 70 Swanston Street, Geelong, VIC 3220, Australia
| | - I Collins
- Dept of Oncology, South West Healthcare, Warrnambool, VIC 3280, Australia and.,School of Medicine, Deakin University, Geelong, VIC 3216, Australia
| | - P Campbell
- Andrew Love Cancer Centre, 70 Swanston Street, Geelong, VIC 3220, Australia.,School of Medicine, Deakin University, Geelong, VIC 3216, Australia
| | - A Patrick
- Barwon South Western Regional Integrated Cancer Services, 70 Swanston Street, Geelong, VIC 3220, Australia
| | - M J Rogers
- Barwon South Western Regional Integrated Cancer Services, 70 Swanston Street, Geelong, VIC 3220, Australia
| |
Collapse
|
7
|
Rogers MJ, Mönkkönen J, Munoz MA. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Bone 2020; 139:115493. [PMID: 32569873 DOI: 10.1016/j.bone.2020.115493] [Citation(s) in RCA: 72] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Revised: 05/09/2020] [Accepted: 06/11/2020] [Indexed: 12/27/2022]
Abstract
Bisphosphonates (BP) are a class of calcium-binding drug used to prevent bone resorption in skeletal disorders such as osteoporosis and metastatic bone disease. They act by selectively targeting bone-resorbing osteoclasts and can be grouped into two classes depending on their intracellular mechanisms of action. Simple BPs cause osteoclast apoptosis after cytoplasmic conversion into toxic ATP analogues. In contrast, nitrogen-containing BPs potently inhibit FPP synthase, an enzyme of the mevalonate (cholesterol biosynthesis) pathway. This results in production of a toxic metabolite (ApppI) and the loss of long-chain isoprenoid lipids required for protein prenylation, a process necessary for the function of small GTPase proteins essential for the survival and activity of osteoclasts. In this review we provide a state-of-the-art overview of these mechanisms of action and a historical perspective of how they were discovered. Finally, we challenge the long-held dogma that BPs act only in the skeleton and highlight recent studies that reveal insights into hitherto unknown effects on tumour-associated and tissue-resident macrophages.
Collapse
Affiliation(s)
- Michael J Rogers
- Garvan Institute of Medical Research, Sydney, Australia; St Vincent's Clinical School, UNSW Sydney, Australia.
| | - Jukka Mönkkönen
- School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Finland.
| | - Marcia A Munoz
- Garvan Institute of Medical Research, Sydney, Australia; St Vincent's Clinical School, UNSW Sydney, Australia.
| |
Collapse
|
8
|
Frost SR, Simpson SW, Levin NE, Quade J, Rogers MJ, Semaw S. Fossil Cercopithecidae from the Early Pliocene Sagantole Formation at Gona, Ethiopia. J Hum Evol 2020; 144:102789. [PMID: 32485477 DOI: 10.1016/j.jhevol.2020.102789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Revised: 03/18/2020] [Accepted: 03/18/2020] [Indexed: 10/24/2022]
Abstract
The Early Pliocene Sagantole Fm. in the Gona Project area, Afar State, Ethiopia, is noted for discoveries of the early hominin Ardipithecus ramidus. A large series of fossil cercopithecid primates dated to between 4.8 and 4.3 Ma has also been collected from these sediments. In this paper, we use qualitative analysis and standard dental and postcranial measures to systematically describe the craniodental remains and tentatively allocate postcrania to taxa where we are able to. We then use these data to compare these specimens to fossil assemblages from contemporary sites, interpret their paleobiology, and discuss implications for the paleoecology of the Gona Sagantole Fm. We recognize three cercopithecid species in the Gona Sagantole Fm. Pliopapio alemui makes up approximately two-thirds of the identifiable specimens; nearly all of the rest are allocated to Kuseracolobus aramisi, and a single molar indicates the presence of a second, somewhat larger but morphologically distinct papionin. Among the Early Pliocene cercopithecids from Gona are also a number of postcranial elements. None of the postcranial remains are directly associated with any of the cranial material. Nonetheless, some of the distal humeri and proximal femora can be tentatively allocated to either Pl. alemui or K. aramisi based on a combination of size, as the latter is approximately 50% larger than the former, and morphology. If these assignments are correct, they suggest K. aramisi was primarily arboreal and similar to most extant colobines, whereas Pl. alemui was more mixed in its substrate use, being more terrestrially adapted than K. aramisi, but less so than extant Papio or Theropithecus. Thus, we interpret the predominance of Pl. alemui over K. aramisi is consistent with a somewhat more open environment at Gona than at Aramis.
Collapse
Affiliation(s)
- Stephen R Frost
- Department of Anthropology, University of Oregon, Eugene, OR, 97403-1218, USA.
| | - Scott W Simpson
- Department of Anatomy, Case Western Reserve University-School of Medicine, 10900 Euclid Avenue, Cleveland, OH, 44106, USA; Laboratory of Physical Anthropology, Cleveland Museum of Natural History, Cleveland, OH, 44106, USA
| | - Naomi E Levin
- Department of Earth and Environmental Sciences, University of Michigan, Ann Arbor, MI, 48109, USA
| | - Jay Quade
- Department of Geosciences, University of Arizona, Tucson, AZ, 85721, USA
| | - Michael J Rogers
- Department of Anthropology, Southern Connecticut State University, 501 Crescent Street, New Haven, CT, 06515-1355, USA
| | - Sileshi Semaw
- Centro Nacional de Investigación Sobre La Evolución Humana, Paseo de Atapuerca 3, 09002, Burgos, Spain; Stone Age Institute & CRAFT Research Center, Gosport, IN, 47408, USA
| |
Collapse
|
9
|
Brown AJ, Sharpe LJ, Rogers MJ. Oxysterols: From physiological tuners to pharmacological opportunities. Br J Pharmacol 2020; 178:3089-3103. [PMID: 32335907 DOI: 10.1111/bph.15073] [Citation(s) in RCA: 40] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2020] [Revised: 04/11/2020] [Accepted: 04/14/2020] [Indexed: 02/06/2023] Open
Abstract
Oxysterols are oxygenated forms of cholesterol generated via autooxidation by free radicals and ROS, or formed enzymically by a variety of enzymes such as those involved in the synthesis of bile acids. Although found at very low concentrations in vivo, these metabolites play key roles in health and disease, particularly in development and regulating immune cell responses, by binding to effector proteins such as LXRα, RORγ and Insig and directly or indirectly regulating transcriptional programmes that affect cell metabolism and function. In this review, we summarise the routes by which oxysterols can be generated and subsequently modified to other oxysterol metabolites and highlight their diverse and profound biological functions and opportunities to alter their levels using pharmacological approaches. LINKED ARTICLES: This article is part of a themed issue on Oxysterols, Lifelong Health and Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.16/issuetoc.
Collapse
Affiliation(s)
- Andrew J Brown
- School of Biotechnology and Biomolecular Sciences, UNSW Sydney, Sydney, New South Wales, Australia
| | - Laura J Sharpe
- School of Biotechnology and Biomolecular Sciences, UNSW Sydney, Sydney, New South Wales, Australia
| | - Michael J Rogers
- Garvan Institute of Medical Research and St Vincent's Clinical School, UNSW Sydney, Sydney, New South Wales, Australia
| |
Collapse
|
10
|
Semaw S, Rogers MJ, Simpson SW, Levin NE, Quade J, Dunbar N, McIntosh WC, Cáceres I, Stinchcomb GE, Holloway RL, Brown FH, Butler RF, Stout D, Everett M. Co-occurrence of Acheulian and Oldowan artifacts with Homo erectus cranial fossils from Gona, Afar, Ethiopia. Sci Adv 2020; 6:eaaw4694. [PMID: 32181331 PMCID: PMC7056306 DOI: 10.1126/sciadv.aaw4694] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/21/2018] [Accepted: 11/19/2019] [Indexed: 06/10/2023]
Abstract
Although stone tools generally co-occur with early members of the genus Homo, they are rarely found in direct association with hominins. We report that both Acheulian and Oldowan artifacts and Homo erectus crania were found in close association at 1.26 million years (Ma) ago at Busidima North (BSN12), and ca. 1.6 to 1.5 Ma ago at Dana Aoule North (DAN5) archaeological sites at Gona, Afar, Ethiopia. The BSN12 partial cranium is robust and large, while the DAN5 cranium is smaller and more gracile, suggesting that H. erectus was probably a sexually dimorphic species. The evidence from Gona shows behavioral diversity and flexibility with a lengthy and concurrent use of both stone technologies by H. erectus, confounding a simple "single species/single technology" view of early Homo.
Collapse
Affiliation(s)
- Sileshi Semaw
- Centro Nacional de Investigación sobre la Evolución Humana (CENIEH), Sierra de Atapuerca 3, 09002 Burgos, Spain
- Stone Age Institute and CRAFT Research Center, 1392 W. Dittemore Rd., Gosport, IN 47408, USA
| | - Michael J. Rogers
- Department of Anthropology, Southern Connecticut State University, 501 Crescent Street, New Haven, CT 06515, USA
| | - Scott W. Simpson
- Department of Anatomy, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
- Laboratory of Physical Anthropology, Cleveland Museum of Natural History, Cleveland, OH 44106, USA
| | - Naomi E. Levin
- Department of Earth and Environmental Sciences, University of Michigan, 1100 North University Avenue, Ann Arbor, MI 48109, USA
| | - Jay Quade
- Department of Geosciences/Desert Laboratory, University of Arizona, Tucson, AZ 85721, USA
| | - Nelia Dunbar
- New Mexico Bureau of Geology and Mineral Resources, Earth and Environmental Science Department, New Mexico Tech, 801 Leroy Place, Socorro, NM 87801-4796, USA
| | - William C. McIntosh
- New Mexico Bureau of Geology and Mineral Resources, Earth and Environmental Science Department, New Mexico Tech, 801 Leroy Place, Socorro, NM 87801-4796, USA
| | - Isabel Cáceres
- Universitat Rovira i Virgili (URV), Avinguda de Catalunya 35, 43002 Tarragona, Spain
- IPHES, Institut Català de Paleoecologia Humana i Evolució Social, Zona Educacional 4–Campus Sescelades URV (Edifici W3), 43007 Tarragona, Spain
| | - Gary E. Stinchcomb
- Watershed Studies Institute and Department of Earth and Environmental Sciences, Murray State University, Murray, KY 42071, USA
| | - Ralph L. Holloway
- Department of Anthropology, Columbia University, 1200 Amsterdam Ave., New York, NY 10027, USA
| | - Francis H. Brown
- The University of Utah, 201 South Presidents Circle Room 201, Salt Lake City, UT 84112, USA
| | - Robert F. Butler
- Department of Physics, University of Portland, Portland, OR 97203, USA
| | - Dietrich Stout
- Department of Anthropology, Emory University, 1557 Dickey Drive, Atlanta, GA 30322, USA
| | - Melanie Everett
- Chevron Energy Technology Company, 1500 Louisiana St., Houston, TX 77002, USA
| |
Collapse
|
11
|
Munoz MA, Jurczyluk J, Simon A, Hissaria P, Arts RJW, Coman D, Boros C, Mehr S, Rogers MJ. Defective Protein Prenylation in a Spectrum of Patients With Mevalonate Kinase Deficiency. Front Immunol 2019; 10:1900. [PMID: 31474985 PMCID: PMC6702261 DOI: 10.3389/fimmu.2019.01900] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2019] [Accepted: 07/26/2019] [Indexed: 01/08/2023] Open
Abstract
The rare autoinflammatory disease mevalonate kinase deficiency (MKD, which includes HIDS and mevalonic aciduria) is caused by recessive, pathogenic variants in the MVK gene encoding mevalonate kinase. Deficiency of this enzyme decreases the synthesis of isoprenoid lipids and thus prevents the normal post-translational prenylation of small GTPase proteins, which then accumulate in their unprenylated form. We recently optimized a sensitive assay capable of detecting unprenylated Rab GTPase proteins in peripheral blood mononuclear cells (PBMCs) and showed that this assay distinguished MKD from other autoinflammatory diseases. We have now analyzed PBMCs from an additional six patients with genetically-confirmed MKD (with different compound heterozygous MVK genotypes), and compared these with PBMCs from three healthy volunteers and four unaffected control individuals heterozygous for the commonest pathogenic variant, MVKV377I. We detected a clear accumulation of unprenylated Rab proteins, as well as unprenylated Rap1A by western blotting, in all six genetically-confirmed MKD patients compared to heterozygous controls and healthy volunteers. Furthermore, in the three subjects for whom measurements of residual mevalonate kinase activity was available, enzymatic activity inversely correlated with the extent of the defect in protein prenylation. Finally, a heterozygous MVKV377I patient presenting with autoinflammatory symptoms did not have defective prenylation, indicating a different cause of disease. These findings support the notion that the extent of loss of enzyme function caused by biallelic MVK variants determines the severity of defective protein prenylation, and the accumulation of unprenylated proteins in PBMCs may be a sensitive and consistent biomarker that could be used to aid, or help rule out, diagnosis of MKD.
Collapse
Affiliation(s)
- Marcia A Munoz
- Bone Biology, Garvan Institute of Medical Research, Sydney & St Vincent's Clinical School, UNSW Sydney, Sydney, NSW, Australia
| | - Julie Jurczyluk
- Bone Biology, Garvan Institute of Medical Research, Sydney & St Vincent's Clinical School, UNSW Sydney, Sydney, NSW, Australia
| | - Anna Simon
- Department of Internal Medicine, Radboudumc Expertise Centre for Immunodeficiency and Autoinflammation, Radboud University Medical Centre, Nijmegen, Netherlands
| | | | - Rob J W Arts
- Department of Internal Medicine, Radboudumc Expertise Centre for Immunodeficiency and Autoinflammation, Radboud University Medical Centre, Nijmegen, Netherlands
| | - David Coman
- Queensland Children's Hospital, Brisbane, QLD, Australia.,School of Medicine, University of Queensland, Brisbane, QLD, Australia.,School of Medicine, Griffith University, Brisbane, QLD, Australia
| | - Christina Boros
- Department of Rheumatology, Women's and Children's Hospital, University of Adelaide Discipline of Paediatrics, Adelaide, SA, Australia
| | - Sam Mehr
- Department of Allergy and Immunology, Royal Children's Hospital, Melbourne, VIC, Australia
| | - Michael J Rogers
- Bone Biology, Garvan Institute of Medical Research, Sydney & St Vincent's Clinical School, UNSW Sydney, Sydney, NSW, Australia
| |
Collapse
|
12
|
Stout D, Rogers MJ, Jaeggi AV, Semaw S. Archaeology and the Origins of Human Cumulative Culture: A Case Study from the Earliest Oldowan at Gona, Ethiopia. Current Anthropology 2019. [DOI: 10.1086/703173] [Citation(s) in RCA: 82] [Impact Index Per Article: 16.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
13
|
Simpson SW, Levin NE, Quade J, Rogers MJ, Semaw S. Ardipithecus ramidus postcrania from the Gona Project area, Afar Regional State, Ethiopia. J Hum Evol 2019; 129:1-45. [DOI: 10.1016/j.jhevol.2018.12.005] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2017] [Revised: 11/26/2018] [Accepted: 12/05/2018] [Indexed: 11/30/2022]
|
14
|
Skinner OP, Jurczyluk J, Baker PJ, Masters SL, Rios Wilks AG, Clearwater MS, Robertson AAB, Schroder K, Mehr S, Munoz MA, Rogers MJ. Lack of protein prenylation promotes NLRP3 inflammasome assembly in human monocytes. J Allergy Clin Immunol 2019; 143:2315-2317.e3. [PMID: 30797829 DOI: 10.1016/j.jaci.2019.02.013] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2018] [Revised: 02/04/2019] [Accepted: 02/14/2019] [Indexed: 10/27/2022]
Affiliation(s)
- Oliver P Skinner
- Bone Biology, Garvan Institute of Medical Research and St Vincent's Clinical School, UNSW Sydney, Sydney, Australia
| | - Julie Jurczyluk
- Bone Biology, Garvan Institute of Medical Research and St Vincent's Clinical School, UNSW Sydney, Sydney, Australia
| | - Paul J Baker
- Inflammation Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
| | - Seth L Masters
- Inflammation Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
| | - Alicia G Rios Wilks
- Bone Biology, Garvan Institute of Medical Research and St Vincent's Clinical School, UNSW Sydney, Sydney, Australia
| | - Misaki S Clearwater
- Bone Biology, Garvan Institute of Medical Research and St Vincent's Clinical School, UNSW Sydney, Sydney, Australia
| | - Avril A B Robertson
- School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Australia
| | - Kate Schroder
- Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia
| | - Sam Mehr
- Department of Allergy/Immunology, Royal Children's Hospital, Melbourne, Australia
| | - Marcia A Munoz
- Bone Biology, Garvan Institute of Medical Research and St Vincent's Clinical School, UNSW Sydney, Sydney, Australia
| | - Michael J Rogers
- Bone Biology, Garvan Institute of Medical Research and St Vincent's Clinical School, UNSW Sydney, Sydney, Australia.
| |
Collapse
|
15
|
Abstract
Drugs called bisphosphonates are used to treat a range of bone diseases, but how do they reach the enzymes that are their target?
Collapse
Affiliation(s)
- Michael J Rogers
- Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, Australia
| | - Marcia A Munoz
- Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, Australia
| |
Collapse
|
16
|
Lee NJ, Ali N, Zhang L, Qi Y, Clarke I, Enriquez RF, Brzozowska M, Lee IC, Rogers MJ, Laybutt DR, Center JR, Baldock PA, Herzog H. Osteoglycin, a novel coordinator of bone and glucose homeostasis. Mol Metab 2018; 13:30-44. [PMID: 29799418 PMCID: PMC6026319 DOI: 10.1016/j.molmet.2018.05.004] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/21/2018] [Revised: 05/02/2018] [Accepted: 05/04/2018] [Indexed: 01/09/2023] Open
Abstract
Objective The skeleton, which is strongly controlled by endocrine factors, has recently been shown to also play an active endocrine role itself, specifically influencing energy metabolism. However, much less is known about this role. Therefore, we sought to identify novel endocrine factors involved in the regulation of both bone mass and whole-body glucose homeostasis. Methods We used transcriptomic and proteomic analysis of Y1 receptor deficient osteoblasts combined with the generation of a novel osteoglycin deficient mouse model and performed comprehensive in vivo phenotype profiling, combined with osteoglycin administration in wildtype mice and human studies. Results Here we identify a novel role for osteoglycin, a secreted proteoglycan, in coordinating bone accretion with changes in energy balance. Using an osteoglycin knockout mouse model, we show that at a whole body level, osteoglycin acts to suppress bone formation and modulate whole body energy supplies by altering glucose uptake through changes in insulin secretion and sensitivity, as well as by altering food intake through central signaling. Examining humans following gastric surgery as a model of negative energy balance, we show that osteoglycin is associated with BMI and lean mass as well as changes in weight, BMI, and glucose levels. Conclusions Thus, we identify osteoglycin as a novel factor involved in the regulation of energy homeostasis and identify a role for it in facilitating the matching of bone acquisition to alterations in energy status. Osteoglycin regulates insulin action, bone mass and food intake in mice. Osteoglycin is associated with changes in weight, BMI and glucose in obese humans. Osteoglycin is a downstream mediator of NPY signaling via osteoblastic Y1 receptors.
Collapse
Affiliation(s)
- N J Lee
- Neuroscience Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; St Vincents Clinical School, UNSW Sydney, Sydney, NSW, Australia
| | - N Ali
- Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
| | - L Zhang
- Neuroscience Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; St Vincents Clinical School, UNSW Sydney, Sydney, NSW, Australia
| | - Y Qi
- Neuroscience Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
| | - I Clarke
- Neuroscience Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
| | - R F Enriquez
- Neuroscience Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
| | - M Brzozowska
- Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; St Vincents Clinical School, UNSW Sydney, Sydney, NSW, Australia
| | - I C Lee
- Neuroscience Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
| | - M J Rogers
- Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; St Vincents Clinical School, UNSW Sydney, Sydney, NSW, Australia
| | - D R Laybutt
- Diabetes and Metabolism Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
| | - J R Center
- Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; St Vincents Clinical School, UNSW Sydney, Sydney, NSW, Australia
| | - P A Baldock
- Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; St Vincents Clinical School, UNSW Sydney, Sydney, NSW, Australia; Faculty of Medicine, UNSW Sydney, Sydney, NSW, Australia
| | - H Herzog
- Neuroscience Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; St Vincents Clinical School, UNSW Sydney, Sydney, NSW, Australia; Faculty of Medicine, UNSW Sydney, Sydney, NSW, Australia.
| |
Collapse
|
17
|
Semaw S, Rogers MJ, Cáceres I, Stout D, Leiss AC. The Early Acheulean ~1.6–1.2 Ma from Gona, Ethiopia: Issues related to the Emergence of the Acheulean in Africa. Vertebrate Paleobiology and Paleoanthropology 2018. [DOI: 10.1007/978-3-319-75985-2_6] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
18
|
Chai RC, McDonald MM, Terry RL, Kovačić N, Down JM, Pettitt JA, Mohanty ST, Shah S, Haffari G, Xu J, Gillespie MT, Rogers MJ, Price JT, Croucher PI, Quinn JMW. Melphalan modifies the bone microenvironment by enhancing osteoclast formation. Oncotarget 2017; 8:68047-68058. [PMID: 28978095 PMCID: PMC5620235 DOI: 10.18632/oncotarget.19152] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2017] [Accepted: 06/02/2017] [Indexed: 11/25/2022] Open
Abstract
Melphalan is a cytotoxic chemotherapy used to treat patients with multiple myeloma (MM). Bone resorption by osteoclasts, by remodeling the bone surface, can reactivate dormant MM cells held in the endosteal niche to promote tumor development. Dormant MM cells can be reactivated after melphalan treatment; however, it is unclear whether melphalan treatment increases osteoclast formation to modify the endosteal niche. Melphalan treatment of mice for 14 days decreased bone volume and the endosteal bone surface, and this was associated with increases in osteoclast numbers. Bone marrow cells (BMC) from melphalan-treated mice formed more osteoclasts than BMCs from vehicle-treated mice, suggesting that osteoclast progenitors were increased. Melphalan also increased osteoclast formation in BMCs and RAW264.7 cells in vitro, which was prevented with the cell stress response (CSR) inhibitor KNK437. Melphalan also increased expression of the osteoclast regulator the microphthalmia-associated transcription factor (MITF), but not nuclear factor of activated T cells 1 (NFATc1). Melphalan increased expression of MITF-dependent cell fusion factors, dendritic cell-specific transmembrane protein (Dc-stamp) and osteoclast-stimulatory transmembrane protein (Oc-stamp) and increased cell fusion. Expression of osteoclast stimulator receptor activator of NFκB ligand (RANKL) was unaffected by melphalan treatment. These data suggest that melphalan stimulates osteoclast formation by increasing osteoclast progenitor recruitment and differentiation in a CSR-dependent manner. Melphalan-induced osteoclast formation is associated with bone loss and reduced endosteal bone surface. As well as affecting bone structure this may contribute to dormant tumor cell activation, which has implications for how melphalan is used to treat patients with MM.
Collapse
Affiliation(s)
- Ryan C Chai
- Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, Australia
| | - Michelle M McDonald
- Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, Australia
| | - Rachael L Terry
- Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, Australia
| | - Nataša Kovačić
- Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, Australia.,Department of Anatomy, University of Zagreb, School of Medicine, Zagreb, Croatia
| | - Jenny M Down
- Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, Australia.,Bone Biology Group, Department of Human Metabolism, Medical School, University of Sheffield, Sheffield, United Kingdom
| | - Jessica A Pettitt
- Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, Australia
| | - Sindhu T Mohanty
- Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, Australia
| | - Shruti Shah
- Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, Australia
| | - Gholamreza Haffari
- Faculty of Information Technology, Monash University, Clayton, Australia
| | - Jiake Xu
- School of Pathology and Laboratory Medicine, The University of Western Australia, Nedlands, Australia
| | - Matthew T Gillespie
- Faculty of Medicine and Health Sciences, Monash University, Clayton, Australia
| | - Michael J Rogers
- Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, Australia
| | - John T Price
- College of Health and Biomedicine, Victoria University, St Albans, Australia.,Australian Institute for Musculoskeletal Science (AIMSS), University of Melbourne, Victoria University and Western Health, St. Albans, Australia
| | - Peter I Croucher
- Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, Australia.,St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, Australia.,School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia
| | - Julian M W Quinn
- Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, Australia
| |
Collapse
|
19
|
Rogers MJ, Matheson L, Garrard B, Maher B, Cowdery S, Luo W, Reed M, Riches S, Pitson G, Ashley DM. Comparison of outcomes for cancer patients discussed and not discussed at a multidisciplinary meeting. Public Health 2017; 149:74-80. [PMID: 28575751 DOI: 10.1016/j.puhe.2017.04.022] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2016] [Revised: 03/15/2017] [Accepted: 04/24/2017] [Indexed: 12/24/2022]
Abstract
OBJECTIVES Comparison of outcomes for cancer patients discussed and not discussed at a multidisciplinary meeting (MDM). STUDY DESIGN Retrospective analysis of the association of MDM discussion with survival. METHODS All newly diagnosed cancer patients from 2009 to 2012, presenting to a large regional cancer service in South West Victoria, Australia (620 colorectal, 657 breast, 593 lung and 511 haematological) were recorded and followed up to 5 years after diagnosis. Treatment patterns and survival of patients whose treatment was discussed at an MDM compared to those who were not, were explored. RESULTS The proportion of patients presented to an MDM within 60 days after diagnosis was 56% (n = 366) for breast cancer, 59% (n = 363) for colorectal cancer, 27% (n = 137) for haematological malignancies and 60% (n = 355) for lung cancer. Seventy-three percent (n = 886) of patients discussed at an MDM had their tumour stage recorded in their medical records while only 52% (n = 604) of patients not discussed had their tumour stage recorded (P < 0.01). We found for haematological and lung cancer patients that those presented to an MDM prior to treatment had a significant reduction in mortality (lung cancer hazard ratio [HR] 0.62, 95% confidence interval [CI] 0.50-0.76, P < 0.01) (haematological cancer HR 0.58, 95% CI 0.35-0.96, P = 0.03) compared to patients whose cases were not discussed at an MDM after adjusting for the potential cofounders of age, stage, comorbidities and treatment. This was not the case for colorectal and breast cancer patients where there was no significant difference. CONCLUSION MDM discussion has been recommended as best practice in the management of cancer patients, however, from a public health perspective this creates potential issues around access and resources. It is likely that MDM presentation patterns and outcomes across tumour streams are linked in complex ways. We believe that our data would demonstrate that these patterns differ across tumour streams and that more detailed work is required to better allocate relatively scarce and potentially costly MDM resources to tumour streams and patient groups that may get the most benefit.
Collapse
Affiliation(s)
- M J Rogers
- Barwon South Western Regional Integrated Cancer Services, Barwon Health, Geelong, Victoria, Australia.
| | - L Matheson
- Barwon South Western Regional Integrated Cancer Services, Barwon Health, Geelong, Victoria, Australia.
| | - B Garrard
- Barwon South Western Regional Integrated Cancer Services, Barwon Health, Geelong, Victoria, Australia.
| | - B Maher
- Barwon South Western Regional Integrated Cancer Services, Barwon Health, Geelong, Victoria, Australia.
| | - S Cowdery
- Barwon South Western Regional Integrated Cancer Services, Barwon Health, Geelong, Victoria, Australia; School of Medicine, Deakin University, Geelong, Victoria, Australia.
| | - W Luo
- Pattern Recognition and Data Analytics, Deakin University, Geelong, Victoria, Australia.
| | - M Reed
- Barwon South Western Regional Integrated Cancer Services, Barwon Health, Geelong, Victoria, Australia.
| | - S Riches
- Barwon South Western Regional Integrated Cancer Services, Barwon Health, Geelong, Victoria, Australia.
| | - G Pitson
- Andrew Love Cancer Centre, Barwon Health, Geelong, Victoria, Australia.
| | - D M Ashley
- Andrew Love Cancer Centre, Barwon Health, Geelong, Victoria, Australia; School of Medicine, Deakin University, Geelong, Victoria, Australia.
| |
Collapse
|
20
|
Munoz MA, Jurczyluk J, Mehr S, Chai RC, Arts RJW, Sheu A, McMahon C, Center JR, Singh-Grewal D, Chaitow J, Campbell DE, Quinn JMW, Alexandrov K, Tnimov Z, Tangye SG, Simon A, Phan TG, Rogers MJ. Defective protein prenylation is a diagnostic biomarker of mevalonate kinase deficiency. J Allergy Clin Immunol 2017; 140:873-875.e6. [PMID: 28501347 DOI: 10.1016/j.jaci.2017.02.033] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2016] [Revised: 12/22/2016] [Accepted: 02/13/2017] [Indexed: 11/26/2022]
Affiliation(s)
- Marcia A Munoz
- Bone Biology Division, Garvan Institute of Medical Research, and St Vincent's Clinical School, UNSW Sydney, Sydney, Australia
| | - Julie Jurczyluk
- Bone Biology Division, Garvan Institute of Medical Research, and St Vincent's Clinical School, UNSW Sydney, Sydney, Australia
| | - Sam Mehr
- Department of Immunology and Allergy, Children's Hospital at Westmead, Sydney, Australia
| | - Ryan C Chai
- Bone Biology Division, Garvan Institute of Medical Research, and St Vincent's Clinical School, UNSW Sydney, Sydney, Australia
| | - Rob J W Arts
- Radboud University Medical Center, Laboratory of Experimental Internal Medicine, Nijmegen, The Netherlands
| | - Angela Sheu
- Bone Biology Division, Garvan Institute of Medical Research, and St Vincent's Clinical School, UNSW Sydney, Sydney, Australia; Department of Endocrinology, St Vincent's Hospital, Darlinghurst, Sydney, Australia
| | - Chelsea McMahon
- Bone Biology Division, Garvan Institute of Medical Research, and St Vincent's Clinical School, UNSW Sydney, Sydney, Australia
| | - Jacqueline R Center
- Bone Biology Division, Garvan Institute of Medical Research, and St Vincent's Clinical School, UNSW Sydney, Sydney, Australia; Department of Endocrinology, St Vincent's Hospital, Darlinghurst, Sydney, Australia
| | - Davinder Singh-Grewal
- Department of Rheumatology, the Sydney Children's Hospitals Network, Randwick and Westmead, Sydney, Australia
| | - Jeffrey Chaitow
- Department of Rheumatology, the Sydney Children's Hospitals Network, Randwick and Westmead, Sydney, Australia
| | - Dianne E Campbell
- Department of Immunology and Allergy, Children's Hospital at Westmead, Sydney, Australia
| | - Julian M W Quinn
- Bone Biology Division, Garvan Institute of Medical Research, and St Vincent's Clinical School, UNSW Sydney, Sydney, Australia
| | - Kirill Alexandrov
- Institute for Molecular Bioscience, the University of Queensland, Queensland, Australia
| | - Zakir Tnimov
- Institute for Molecular Bioscience, the University of Queensland, Queensland, Australia
| | - Stuart G Tangye
- Immunology Division, Garvan Institute of Medical Research, and St Vincent's Clinical School, UNSW Australia, Sydney, Australia
| | - Anna Simon
- Radboud University Medical Center, Laboratory of Experimental Internal Medicine, Nijmegen, The Netherlands
| | - Tri Giang Phan
- Immunology Division, Garvan Institute of Medical Research, and St Vincent's Clinical School, UNSW Australia, Sydney, Australia
| | - Michael J Rogers
- Bone Biology Division, Garvan Institute of Medical Research, and St Vincent's Clinical School, UNSW Sydney, Sydney, Australia.
| |
Collapse
|
21
|
Lawson MA, McDonald MM, Kovacic N, Hua Khoo W, Terry RL, Down J, Kaplan W, Paton-Hough J, Fellows C, Pettitt JA, Neil Dear T, Van Valckenborgh E, Baldock PA, Rogers MJ, Eaton CL, Vanderkerken K, Pettit AR, Quinn JMW, Zannettino ACW, Phan TG, Croucher PI. Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun 2015; 6:8983. [PMID: 26632274 PMCID: PMC4686867 DOI: 10.1038/ncomms9983] [Citation(s) in RCA: 248] [Impact Index Per Article: 27.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2015] [Accepted: 10/23/2015] [Indexed: 12/25/2022] Open
Abstract
Multiple myeloma is largely incurable, despite development of therapies that target myeloma cell-intrinsic pathways. Disease relapse is thought to originate from dormant myeloma cells, localized in specialized niches, which resist therapy and repopulate the tumour. However, little is known about the niche, and how it exerts cell-extrinsic control over myeloma cell dormancy and reactivation. In this study, we track individual myeloma cells by intravital imaging as they colonize the endosteal niche, enter a dormant state and subsequently become activated to form colonies. We demonstrate that dormancy is a reversible state that is switched ‘on' by engagement with bone-lining cells or osteoblasts, and switched ‘off' by osteoclasts remodelling the endosteal niche. Dormant myeloma cells are resistant to chemotherapy that targets dividing cells. The demonstration that the endosteal niche is pivotal in controlling myeloma cell dormancy highlights the potential for targeting cell-extrinsic mechanisms to overcome cell-intrinsic drug resistance and prevent disease relapse. Therapy resistant dormant myeloma cells contribute to disease relapse. Here, the authors use intravital microscopy to track the location of these cells and demonstrate that they hone to the endosteal niche within the bone.
Collapse
Affiliation(s)
- Michelle A Lawson
- Department of Oncology, University of Sheffield Medical School, University of Sheffield, Beech Hill Road, Sheffield, South Yorkshire S10 2RX, UK.,Mellanby Centre for Bone Research, University of Sheffield Medical School, University of Sheffield, Beech Hill Road, Sheffield, South Yorkshire S10 2RX, UK
| | - Michelle M McDonald
- Garvan Institute of Medical Research, 384 Victoria Street, Sydney, New South Wales 2010, Australia.,St Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, New South Wales 2010, Australia
| | - Natasa Kovacic
- Garvan Institute of Medical Research, 384 Victoria Street, Sydney, New South Wales 2010, Australia
| | - Weng Hua Khoo
- Garvan Institute of Medical Research, 384 Victoria Street, Sydney, New South Wales 2010, Australia.,School of Biotechnology and Biomolecular Sciences, UNSW Australia, Sydney, New South Wales 2010, Australia
| | - Rachael L Terry
- Garvan Institute of Medical Research, 384 Victoria Street, Sydney, New South Wales 2010, Australia.,St Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, New South Wales 2010, Australia
| | - Jenny Down
- Garvan Institute of Medical Research, 384 Victoria Street, Sydney, New South Wales 2010, Australia
| | - Warren Kaplan
- Garvan Institute of Medical Research, 384 Victoria Street, Sydney, New South Wales 2010, Australia.,St Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, New South Wales 2010, Australia
| | - Julia Paton-Hough
- Department of Oncology, University of Sheffield Medical School, University of Sheffield, Beech Hill Road, Sheffield, South Yorkshire S10 2RX, UK.,Mellanby Centre for Bone Research, University of Sheffield Medical School, University of Sheffield, Beech Hill Road, Sheffield, South Yorkshire S10 2RX, UK
| | - Clair Fellows
- Department of Oncology, University of Sheffield Medical School, University of Sheffield, Beech Hill Road, Sheffield, South Yorkshire S10 2RX, UK.,Mellanby Centre for Bone Research, University of Sheffield Medical School, University of Sheffield, Beech Hill Road, Sheffield, South Yorkshire S10 2RX, UK
| | - Jessica A Pettitt
- Garvan Institute of Medical Research, 384 Victoria Street, Sydney, New South Wales 2010, Australia
| | - T Neil Dear
- South Australian Health and Medical Research Institute, Adelaide, South Australia 5000, Australia
| | - Els Van Valckenborgh
- Department of Hematology and Immunology, Vrije Universiteit Brussel, Brussels 1090, Belgium
| | - Paul A Baldock
- Garvan Institute of Medical Research, 384 Victoria Street, Sydney, New South Wales 2010, Australia.,St Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, New South Wales 2010, Australia
| | - Michael J Rogers
- Garvan Institute of Medical Research, 384 Victoria Street, Sydney, New South Wales 2010, Australia.,St Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, New South Wales 2010, Australia
| | - Colby L Eaton
- Mellanby Centre for Bone Research, University of Sheffield Medical School, University of Sheffield, Beech Hill Road, Sheffield, South Yorkshire S10 2RX, UK.,Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, University of Sheffield, Beech Hill Road, Sheffield, South Yorkshire S10 2RX, UK
| | - Karin Vanderkerken
- Department of Hematology and Immunology, Vrije Universiteit Brussel, Brussels 1090, Belgium
| | - Allison R Pettit
- Mater Research Institute, The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland 4102, Australia
| | - Julian M W Quinn
- Garvan Institute of Medical Research, 384 Victoria Street, Sydney, New South Wales 2010, Australia
| | - Andrew C W Zannettino
- South Australian Health and Medical Research Institute, Adelaide, South Australia 5000, Australia.,School of Medical Sciences, University of Adelaide, Frome Road, Adelaide, South Australia 5000, Australia
| | - Tri Giang Phan
- Garvan Institute of Medical Research, 384 Victoria Street, Sydney, New South Wales 2010, Australia.,St Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, New South Wales 2010, Australia
| | - Peter I Croucher
- Garvan Institute of Medical Research, 384 Victoria Street, Sydney, New South Wales 2010, Australia.,St Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, New South Wales 2010, Australia
| |
Collapse
|
22
|
Ali N, Jurczyluk J, Shay G, Tnimov Z, Alexandrov K, Munoz MA, Skinner OP, Pavlos NJ, Rogers MJ. A highly sensitive prenylation assay reveals in vivo effects of bisphosphonate drug on the Rab prenylome of macrophages outside the skeleton. Small GTPases 2015; 6:202-11. [PMID: 26399387 PMCID: PMC4905276 DOI: 10.1080/21541248.2015.1085485] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Bisphosphonate drugs such as zoledronic acid (ZOL), used for the treatment of common bone disorders, target the skeleton and inhibit bone resorption by preventing the prenylation of small GTPases in bone-destroying osteoclasts. Increasing evidence indicates that bisphosphonates also have pleiotropic effects outside the skeleton, most likely via cells of the monocyte/macrophage lineage exposed to nanomolar circulating drug concentrations. However, no effects of such low concentrations of ZOL have been reported using existing approaches. We have optimized a highly sensitive in vitro prenylation assay utilizing recombinant geranylgeranyltransferases to enable the detection of subtle effects of ZOL on the prenylation of Rab- and Rho-family GTPases. Using this assay, we found for the first time that concentrations of ZOL as low as 10nM caused inhibition of Rab prenylation in J774 macrophages following prolonged cell culture. By combining the assay with quantitative mass spectrometry we identified an accumulation of 18 different unprenylated Rab proteins in J774 cells after nanomolar ZOL treatment, with a >7-fold increase in the unprenylated form of Rab proteins associated with the endophagosome pathway (Rab1, Rab5, Rab6, Rab7, Rab11, Rab14 and Rab21). Finally, we also detected a clear effect of subcutaneous ZOL administration in vivo on the prenylation of Rab1A, Rab5B, Rab7A and Rab14 in mouse peritoneal macrophages, confirming that systemic treatment with bisphosphonate drug can inhibit prenylation in myeloid cells in vivo outside the skeleton. These observations begin a new era in defining the precise pharmacological actions of bisphosphonate drugs on the prenylation of small GTPases in vivo.
Collapse
Affiliation(s)
- Naveid Ali
- a Garvan Institute of Medical Research and St Vincent's Clinical School; UNSW Australia ; Sydney , Australia
| | - Julie Jurczyluk
- a Garvan Institute of Medical Research and St Vincent's Clinical School; UNSW Australia ; Sydney , Australia
| | - Gemma Shay
- b Institute of Medical Sciences; University of Aberdeen ; Aberdeen , UK.,e H. Lee Moffitt Cancer Center ; Tampa , FL USA
| | - Zakir Tnimov
- c Institute for Molecular Bioscience; The University of Queensland ; Queensland , Australia
| | - Kirill Alexandrov
- c Institute for Molecular Bioscience; The University of Queensland ; Queensland , Australia
| | - Marcia A Munoz
- a Garvan Institute of Medical Research and St Vincent's Clinical School; UNSW Australia ; Sydney , Australia
| | - Oliver P Skinner
- a Garvan Institute of Medical Research and St Vincent's Clinical School; UNSW Australia ; Sydney , Australia
| | | | - Michael J Rogers
- a Garvan Institute of Medical Research and St Vincent's Clinical School; UNSW Australia ; Sydney , Australia
| |
Collapse
|
23
|
Croucher PI, Parker BS, Corcoran N, Rogers MJ. Bone Turnover Markers and Prostate Cancer: Not Just a Measure of Bone Disease? Eur Urol 2014; 68:51-2. [PMID: 25466938 DOI: 10.1016/j.eururo.2014.10.041] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2014] [Accepted: 10/27/2014] [Indexed: 11/20/2022]
Affiliation(s)
- Peter I Croucher
- Garvan Institute of Medical Research, Darlinghurst, Australia; St Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, Australia.
| | - Belinda S Parker
- Department of Biochemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Australia
| | - Niall Corcoran
- Department of Surgery, University of Melbourne, Royal Melbourne Hospital, Melbourne, Australia
| | - Michael J Rogers
- Garvan Institute of Medical Research, Darlinghurst, Australia; St Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, Australia
| |
Collapse
|
24
|
Itzstein C, Coxon FP, Rogers MJ. The regulation of osteoclast function and bone resorption by small GTPases. Small GTPases 2014; 2:117-130. [PMID: 21776413 DOI: 10.4161/sgtp.2.3.16453] [Citation(s) in RCA: 109] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2011] [Revised: 04/22/2011] [Accepted: 05/10/2011] [Indexed: 01/11/2023] Open
Abstract
Osteoclasts are multinucleated cells that are responsible for resorption of bone, and increased activity of these cells is associated with several common bone diseases, including postmenopausal osteoporosis. Upon adhesion to bone, osteoclasts become polarized and reorganise their cytoskeleton and membrane to form unique domains including the sealing zone (SZ), which is a dense ring of F-actin-rich podosomes delimiting the ruffled border (RB), where protons and proteases are secreted to demineralise and degrade the bone matrix, respectively. These processes are dependent on the activity of small GTPases. Rho GTPases are well known to control the organization of F-actin and adhesion structures of different cell types, affecting subsequently their migration. In osteoclasts, RhoA, Rac, Cdc42, RhoU and also Arf6 regulate podosome assembly and their organization into the SZ. By contrast, the formation of the RB involves vesicular trafficking pathways that are regulated by the Rab family of GTPases, in particular lysosomal Rab7. Finally, osteoclast survival is dependent on the activity of Ras GTPases. The correct function of almost all these GTPases is absolutely dependent on post-translational prenylation, which enables them to localize to specific target membranes. Bisphosphonate drugs, which are widely used in the treatment of bone diseases such as osteoporosis, act by preventing the prenylation of small GTPases, resulting in the loss of the SZ and RB and therefore inhibition of osteoclast activity, as well as inducing osteoclast apoptosis. In this review we summarize current understanding of the role of specific prenylated small GTPases in osteoclast polarization, function and survival.
Collapse
Affiliation(s)
- Cecile Itzstein
- Musculoskeletal Research Programme; Institute of Medical Sciences; University of Aberdeen; Aberdeen, Scotland UK
| | | | | |
Collapse
|
25
|
Junankar S, Shay G, Jurczyluk J, Ali N, Down J, Pocock N, Parker A, Nguyen A, Sun S, Kashemirov B, McKenna CE, Croucher PI, Swarbrick A, Weilbaecher K, Phan TG, Rogers MJ. Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer. Cancer Discov 2014; 5:35-42. [PMID: 25312016 DOI: 10.1158/2159-8290.cd-14-0621] [Citation(s) in RCA: 107] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
UNLABELLED Recent clinical trials have shown that bisphosphonate drugs improve breast cancer patient survival independent of their antiresorptive effects on the skeleton. However, because bisphosphonates bind rapidly to bone mineral, the exact mechanisms of their antitumor action, particularly on cells outside of bone, remain unknown. Here, we used real-time intravital two-photon microscopy to show extensive leakage of fluorescent bisphosphonate from the vasculature in 4T1 mouse mammary tumors, where it initially binds to areas of small, granular microcalcifications that are engulfed by tumor-associated macrophages (TAM), but not tumor cells. Importantly, we also observed uptake of radiolabeled bisphosphonate in the primary breast tumor of a patient and showed the resected tumor to be infiltrated with TAMs and to contain similar granular microcalcifications. These data represent the first compelling in vivo evidence that bisphosphonates can target cells in tumors outside the skeleton and that their antitumor activity is likely to be mediated via TAMs. SIGNIFICANCE Bisphosphonates are assumed to act solely in bone. However, mouse models and clinical trials show that they have surprising antitumor effects outside bone. We provide unequivocal evidence that bisphosphonates target TAMs, but not tumor cells, to exert their extraskeletal effects, offering a rationale for use in patients with early disease.
Collapse
Affiliation(s)
- Simon Junankar
- Garvan Institute of Medical Research and St. Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, Australia
| | - Gemma Shay
- Division of Applied Medicine, University of Aberdeen, Aberdeen, United Kingdom
| | - Julie Jurczyluk
- Garvan Institute of Medical Research and St. Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, Australia
| | - Naveid Ali
- Garvan Institute of Medical Research and St. Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, Australia
| | - Jenny Down
- Garvan Institute of Medical Research and St. Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, Australia
| | - Nicholas Pocock
- Garvan Institute of Medical Research and St. Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, Australia. Department of Nuclear Medicine, St. Vincent's Hospital, Sydney, Australia
| | - Andrew Parker
- Department of Pathology, St. Vincent's Hospital, Sydney, Australia
| | - Akira Nguyen
- Garvan Institute of Medical Research and St. Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, Australia
| | - Shuting Sun
- University of Southern California, Los Angeles, California
| | | | | | - Peter I Croucher
- Garvan Institute of Medical Research and St. Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, Australia
| | - Alexander Swarbrick
- Garvan Institute of Medical Research and St. Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, Australia
| | - Katherine Weilbaecher
- Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
| | - Tri Giang Phan
- Garvan Institute of Medical Research and St. Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, Australia
| | - Michael J Rogers
- Garvan Institute of Medical Research and St. Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, Australia.
| |
Collapse
|
26
|
Affiliation(s)
- M J Rogers
- Laboratory of Genetics, National Cancer Institute, Bethesda, MD 20205, USA
| |
Collapse
|
27
|
Das S, Edwards PA, Crockett JC, Rogers MJ. Upregulation of endogenous farnesyl diphosphate synthase overcomes the inhibitory effect of bisphosphonate on protein prenylation in Hela cells. Biochim Biophys Acta Mol Cell Biol Lipids 2014; 1841:569-73. [DOI: 10.1016/j.bbalip.2013.12.010] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2013] [Revised: 12/12/2013] [Accepted: 12/17/2013] [Indexed: 11/29/2022]
|
28
|
Naylor AJ, Azzam E, Smith S, Croft A, Poyser C, Duffield JS, Huso DL, Gay S, Ospelt C, Cooper MS, Isacke C, Goodyear SR, Rogers MJ, Buckley CD. The mesenchymal stem cell marker CD248 (endosialin) is a negative regulator of bone formation in mice. ACTA ACUST UNITED AC 2013; 64:3334-43. [PMID: 22674221 DOI: 10.1002/art.34556] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
OBJECTIVE CD248 (tumor endothelial marker 1/endosialin) is found on stromal cells and is highly expressed during malignancy and inflammation. Studies have shown a reduction in inflammatory arthritis in CD248-knockout (CD248(-/-) ) mice. The aim of the present study was to investigate the functional effect of genetic deletion of CD248 on bone mass. METHODS Western blotting, polymerase chain reaction, and immunofluorescence were used to investigate the expression of CD248 in humans and mice. Micro-computed tomography and the 3-point bending test were used to measure bone parameters and mechanical properties of the tibiae of 10-week-old wild-type (WT) or CD248(-/-) mice. Human and mouse primary osteoblasts were cultured in medium containing 10 mM β-glycerophosphate and 50 μg/ml ascorbic acid to induce mineralization, and then treated with platelet-derived growth factor BB (PDGF-BB). The mineral apposition rate in vivo was calculated by identifying newly formed bone via calcein labeling. RESULTS Expression of CD248 was seen in human and mouse osteoblasts, but not osteoclasts. CD248(-/-) mouse tibiae had higher bone mass and superior mechanical properties (increased load required to cause fracture) compared to WT mice. Primary osteoblasts from CD248(-/-) mice induced increased mineralization in vitro and produced increased bone over 7 days in vivo. There was no decrease in bone mineralization and no increase in proliferation of osteoblasts in response to stimulation with PDGF-BB, which could be attributed to a defect in PDGF signal transduction in the CD248(-/-) mice. CONCLUSION There is an unmet clinical need to address rheumatoid arthritis-associated bone loss. Genetic deletion of CD248 in mice results in high bone mass due to increased osteoblast-mediated bone formation, suggesting that targeting CD248 in rheumatoid arthritis may have the effect of increasing bone mass in addition to the previously reported effect of reducing inflammation.
Collapse
|
29
|
Whyte LS, Ford L, Ridge SA, Cameron GA, Rogers MJ, Ross RA. Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro. Br J Pharmacol 2012; 165:2584-97. [PMID: 21649637 DOI: 10.1111/j.1476-5381.2011.01519.x] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND AND PURPOSE Both CB(1) and CB(2) cannabinoid receptors have been shown to play a role in bone metabolism. Crucially, previous studies have focussed on the effects of cannabinoid ligands in murine bone cells. This study aimed to investigate the effects of cannabinoids on human bone cells in vitro. EXPERIMENTAL APPROACH Quantitative RT-PCR was used to determine expression of cannabinoid receptors and liquid chromatography-electrospray ionization tandem mass spectrometry was used to determine the presence of endocannabinoids in human bone cells. The effect of cannabinoids on human osteoclast formation, polarization and resorption was determined by assessing the number of cells expressing α(v) β(3) or with F-actin rings, or measurement of resorption area. KEY RESULTS Human osteoclasts express both CB(1) and CB(2) receptors. CB(2) expression was significantly higher in human monocytes compared to differentiated osteoclasts. Furthermore, the differentiation of human osteoclasts from monocytes was associated with a reduction in 2-AG levels and an increase in anandamide (AEA) levels. Treatment of osteoclasts with LPS significantly increased levels of AEA. Nanomolar concentrations of AEA and the synthetic agonists CP 55 940 and JWH015 stimulated human osteoclast polarization and resorption; these effects were attenuated in the presence of CB(1) and/or CB(2) antagonists. CONCLUSIONS AND IMPLICATIONS Low concentrations of cannabinoids activate human osteoclasts in vitro. There is a dynamic regulation of the expression of the CB(2) receptor and the production of the endocannabinoids during the differentiation of human bone cells. These data suggest that small molecules modulating the endocannabinoid system could be important therapeutics in human bone disease. LINKED ARTICLES This article is part of a themed section on Cannabinoids in Biology and Medicine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.165.issue-8. To view Part I of Cannabinoids in Biology and Medicine visit http://dx.doi.org/10.1111/bph.2011.163.issue-7.
Collapse
Affiliation(s)
- L S Whyte
- Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.
| | | | | | | | | | | |
Collapse
|
30
|
Roelofs AJ, Stewart CA, Sun S, Błażewska KM, Kashemirov BA, McKenna CE, Russell RGG, Rogers MJ, Lundy MW, Ebetino FH, Coxon FP. Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo. J Bone Miner Res 2012; 27:835-47. [PMID: 22228189 DOI: 10.1002/jbmr.1543] [Citation(s) in RCA: 89] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Bisphosphonates are widely used antiresorptive drugs that bind to calcium. It has become evident that these drugs have differing affinities for bone mineral; however, it is unclear whether such differences affect their distribution on mineral surfaces. In this study, fluorescent conjugates of risedronate, and its lower-affinity analogues deoxy-risedronate and 3-PEHPC, were used to compare the localization of compounds with differing mineral affinities in vivo. Binding to dentine in vitro confirmed differences in mineral binding between compounds, which was influenced predominantly by the characteristics of the parent compound but also by the choice of fluorescent tag. In growing rats, all compounds preferentially bound to forming endocortical as opposed to resorbing periosteal surfaces in cortical bone, 1 day after administration. At resorbing surfaces, lower-affinity compounds showed preferential binding to resorption lacunae, whereas the highest-affinity compound showed more uniform labeling. At forming surfaces, penetration into the mineralizing osteoid was found to inversely correlate with mineral affinity. These differences in distribution at resorbing and forming surfaces were not observed at quiescent surfaces. Lower-affinity compounds also showed a relatively higher degree of labeling of osteocyte lacunar walls and labeled lacunae deeper within cortical bone, indicating increased penetration of the osteocyte canalicular network. Similar differences in mineralizing surface and osteocyte network penetration between high- and low-affinity compounds were evident 7 days after administration, with fluorescent conjugates at forming surfaces buried under a new layer of bone. Fluorescent compounds were incorporated into these areas of newly formed bone, indicating that "recycling" had occurred, albeit at very low levels. Taken together, these findings indicate that the bone mineral affinity of bisphosphonates is likely to influence their distribution within the skeleton.
Collapse
Affiliation(s)
- Anke J Roelofs
- Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Hughes A, Kleine-Albers J, Helfrich MH, Ralston SH, Rogers MJ. A class III semaphorin (Sema3e) inhibits mouse osteoblast migration and decreases osteoclast formation in vitro. Calcif Tissue Int 2012; 90:151-62. [PMID: 22227882 PMCID: PMC3271215 DOI: 10.1007/s00223-011-9560-7] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2011] [Accepted: 12/04/2011] [Indexed: 12/11/2022]
Abstract
Originally identified as axonal guidance cues, semaphorins are expressed throughout many different tissues and regulate numerous non-neuronal processes. We demonstrate that most class III semaphorins are expressed in mouse osteoblasts and are differentially regulated by cell growth and differentiation: Sema3d expression is increased and Sema3e expression decreased during proliferation in culture, while expression of Sema3a is unaffected by cell density but increases in cultures of mineralizing osteoblasts. Expression of Sema3a, -3e, and -3d is also differentially regulated by osteogenic stimuli; inhibition of GSK3β decreased expression of Sema3a and -3e, while 1,25-(OH)(2)D(3) increased expression of Sema3e. Parathyroid hormone had no effect on expression of Sema3a, -3b, or -3d. Osteoblasts, macrophages, and osteoclasts express the Sema3e receptor PlexinD1, suggesting an autocrine and paracrine role for Sema3e. No effects of recombinant Sema3e on osteoblast proliferation, differentiation, or mineralization were observed; but Sema3e did inhibit the migration of osteoblasts in a wound-healing assay. The formation of multinucleated, tartrate-resistant acid phosphatase-positive osteoclasts was decreased by 81% in cultures of mouse bone marrow macrophages incubated with 200 ng/mL Sema3e. Correspondingly, decreased expression of osteoclast markers (Itgb3, Acp5, Cd51, Nfatc1, CalcR, and Ctsk) was observed by qPCR in macrophage cultures differentiated in the presence of Sema3e. Our results demonstrate that class III semaphorins are expressed by osteoblasts and differentially regulated by differentiation, mineralization, and osteogenic stimuli. Sema3e is a novel inhibitor of osteoclast formation in vitro and may play a role in maintaining local bone homeostasis, potentially acting as a coupling factor between osteoclasts and osteoblasts.
Collapse
Affiliation(s)
- Alun Hughes
- Musculoskeletal Research Programme, School of Medicine & Dentistry, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen AB252ZD UK
| | - Jennifer Kleine-Albers
- Musculoskeletal Research Programme, School of Medicine & Dentistry, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen AB252ZD UK
| | - Miep H. Helfrich
- Musculoskeletal Research Programme, School of Medicine & Dentistry, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen AB252ZD UK
| | - Stuart H. Ralston
- Molecular Medicine Centre, Western General Hospital, University of Edinburgh, Crewe Road, Edinburgh, EH42XU UK
| | - Michael J. Rogers
- Musculoskeletal Research Programme, School of Medicine & Dentistry, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen AB252ZD UK
| |
Collapse
|
32
|
Abstract
Newborn rabbits provide a useful and readily available source of authentic mature osteoclasts, which can be easily isolated directly from the long bones in relatively large numbers, compared to other rodents. Primary cultures of authentic rabbit osteoclasts on resorbable substrates in vitro are an ideal model of osteoclast behaviour in vivo, and for some studies may be preferable to osteoclast-like cells generated in vitro from bone marrow cultures or from human peripheral blood, for example in assessing osteoclast-mediated bone resorption independently of effects on osteoclast formation. Rabbits also provide a particularly useful model for determining the effects of pharmacological agents on osteoclasts in vivo, by isolating osteoclasts using immunomagnetic bead separation (with an antibody to α(V)β(3)) at the desired time following in vivo administration of the drug. Since osteoclasts are abundant in newborn rabbits, sufficient numbers of osteoclasts can be retrieved using this method for molecular and biochemical analyses.
Collapse
Affiliation(s)
- Fraser P Coxon
- Musculoskeletal Research Programme, Division of Applied Medicine, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK.
| | | | | |
Collapse
|
33
|
Błażewska KM, Ni F, Haiges R, Kashemirov BA, Coxon FP, Stewart CA, Baron R, Rogers MJ, Seabra MC, Ebetino FH, McKenna CE. Synthesis, stereochemistry and SAR of a series of minodronate analogues as RGGT inhibitors. Eur J Med Chem 2011; 46:4820-6. [DOI: 10.1016/j.ejmech.2011.04.063] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2011] [Revised: 04/26/2011] [Accepted: 04/27/2011] [Indexed: 11/30/2022]
|
34
|
Crockett JC, Mellis DJ, Shennan KI, Duthie A, Greenhorn J, Wilkinson DI, Ralston SH, Helfrich MH, Rogers MJ. Signal peptide mutations in RANK prevent downstream activation of NF-κB. J Bone Miner Res 2011; 26:1926-38. [PMID: 21472776 PMCID: PMC3378713 DOI: 10.1002/jbmr.399] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/05/2022]
Abstract
Familial expansile osteolysis and related disorders are caused by heterozygous tandem duplication mutations in the signal peptide region of the gene encoding receptor activator of NF-κB (RANK), a receptor critical for osteoclast formation and function. Previous studies have shown that overexpression of these mutant proteins causes constitutive activation of NF-κB signaling in vitro, and it has been assumed that this accounts for the focal osteolytic lesions that are seen in vivo. We show here that constitutive activation of NF-κB occurred in HEK293 cells overexpressing wild-type or mutant RANK but not in stably transfected cell lines expressing low levels of each RANK gene. Importantly, only cells expressing wild-type RANK demonstrated ligand-dependent activation of NF-κB. When overexpressed, mutant RANK did not localize to the plasma membrane but localized to extensive areas of organized smooth endoplasmic reticulum, whereas, as expected, wild-type RANK was detected at the plasma membrane and in the Golgi apparatus. This intracellular accumulation of the mutant proteins is probably the result of lack of signal peptide cleavage because, using two in vitro translation systems, we demonstrate that the mutations in RANK prevent cleavage of the signal peptide. In conclusion, signal peptide mutations lead to accumulation of RANK in the endoplasmic reticulum and prevent direct activation by RANK ligand. These results strongly suggest that the increased osteoclast formation/activity caused by these mutations cannot be explained by studying the homozygous phenotype alone but requires further detailed investigation of the heterozygous expression of the mutant RANK proteins.
Collapse
Affiliation(s)
- Julie C Crockett
- Musculoskeletal Research Program, University of Aberdeen Medical School, Institute of Medical Sciences, Foresterhill, Aberdeen, United Kingdom.
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Affiliation(s)
- Julie C Crockett
- Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.
| | | | | | | | | |
Collapse
|
36
|
Moriceau G, Roelofs AJ, Brion R, Redini F, Ebetion FH, Rogers MJ, Heymann D. Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth. Cancer 2011; 118:750-60. [DOI: 10.1002/cncr.26336] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2011] [Revised: 05/16/2011] [Accepted: 05/16/2011] [Indexed: 11/07/2022]
|
37
|
Thompson K, Keech F, McLernon DJ, Vinod K, May RJ, Simpson WG, Rogers MJ, Reid DM. Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women. Bone 2011; 49:140-5. [PMID: 21047568 DOI: 10.1016/j.bone.2010.10.177] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/24/2010] [Revised: 10/26/2010] [Accepted: 10/26/2010] [Indexed: 10/18/2022]
Abstract
The acute-phase response (APR) to aminobisphosphonates is triggered by activation of γδ T cells, resulting in pro-inflammatory cytokine release. Statins prevent aminobisphosphonate-induced γδ T cell activation in vitro, raising the possibility that statins might prevent the APR in vivo. The objective of this study was to determine whether fluvastatin prevents the APR to zoledronic acid in post-menopausal women. A double-blind, randomised, placebo-controlled study was conducted in 60 healthy, post-menopausal, female volunteers (mean age 60.6 ± 4.0). Volunteers received 5 mg zoledronic acid by intravenous infusion, and either three times 40 mg fluvastatin (0 hr, 24 hr and 48 hr), 40 mg fluvastatin (0 hr) plus placebo (24 hr and 48 hr), or placebo (0 hr, 24 hr and 48 hr), orally. Post-infusion symptoms were assessed by questionnaire. Changes in γδ T cell levels, pro-inflammatory cytokines (TNFα, IFNγ, IL-6) and C-reactive protein (CRP) were measured in peripheral blood at various time-points post-infusion. Zoledronic acid administration triggered increased serum levels of TNFα, IFNγ, IL-6 and CRP in ≥70% of study volunteers, whilst characteristic APR symptoms were observed in >50% of participants. Zoledronic acid also induced a transient fall in circulating Vγ9Vδ2 T cell levels at 48 hr, consistent with Vγ9Vδ2 T cell activation. Concurrent fluvastatin administration did not prevent zoledronic acid-induced cytokine release, alter circulating Vγ9Vδ2 T cell levels, nor diminish the frequency or severity of APR symptoms. In conclusion, intravenous zoledronic acid induced pro-inflammatory cytokine release and APR symptoms in the majority of study participants, which was not prevented by co-administration of fluvastatin.
Collapse
Affiliation(s)
- Keith Thompson
- Division of Applied Medicine, University of Aberdeen, UK.
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Coxon FP, Taylor A, Stewart CA, Baron R, Seabra MC, Ebetino FH, Rogers MJ. The gunmetal mouse reveals Rab geranylgeranyl transferase to be the major molecular target of phosphonocarboxylate analogues of bisphosphonates. Bone 2011; 49:111-21. [PMID: 21419243 DOI: 10.1016/j.bone.2011.03.686] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/28/2011] [Revised: 03/09/2011] [Accepted: 03/11/2011] [Indexed: 11/24/2022]
Abstract
The described ability of phosphonocarboxylate analogues of bisphosphonates (BPs) to inhibit Rab geranylgeranyl transferase (RGGT) is thought to be the mechanism underlying their cellular effects, including their ability to reduce macrophage cell viability and to inhibit osteoclast-mediated resorption. However, until now the possibility that at least some of the effects of these drugs may be mediated through other targets has not been excluded. Since RGGT is the most distal enzyme in the process of Rab prenylation, it has not proved possible to confirm the mechanism underlying the effects of these drugs by adding back downstream intermediates of the mevalonate pathway, the approach used to demonstrate that bisphosphonates act through this pathway. We now confirm that RGGT is the major pharmacological target of phosphonocarboxylates by using several alternative approaches. Firstly, analysis of several different phosphonocarboxylate drugs demonstrates a very good correlation between the ability of these drugs to inhibit RGGT with their ability to: (a) reduce macrophage cell viability; (b) induce apoptosis; and (c) induce vacuolation in rabbit osteoclasts. Secondly, we have found that cells from the gunmetal (gm/gm) mouse, which bear a homozygous mutation in RGGT that results in ~80% reduced activity of this enzyme compared to wild-type or heterozygous mice, are more sensitive to the effects of active phosphonocarboxylates (including reducing macrophage cell viability, inhibiting osteoclast formation and inhibiting fluid-phase endocytosis), confirming that these effects are mediated through inhibition of RGGT. In conclusion, these data demonstrate that all of the pharmacological effects of phosphonocarboxylates found thus far appear to be mediated through the specific inhibition of RGGT, highlighting the potential therapeutic value of this class of drugs.
Collapse
Affiliation(s)
- Fraser P Coxon
- Musculoskeletal Programme, Division of Applied Medicine, Institute of Medical Sciences, University of Aberdeen, Foresterhill, UK.
| | | | | | | | | | | | | |
Collapse
|
39
|
Rogers MJ, Crockett JC, Coxon FP, Mönkkönen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011; 49:34-41. [PMID: 21111853 DOI: 10.1016/j.bone.2010.11.008] [Citation(s) in RCA: 353] [Impact Index Per Article: 27.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/07/2010] [Revised: 11/08/2010] [Accepted: 11/09/2010] [Indexed: 11/26/2022]
Abstract
This review describes the key discoveries over the last 15 years that have led to a clearer understanding of the molecular mechanisms by which bisphosphonate drugs inhibit bone resorption. Once released from bone mineral surfaces during bone resorption, these agents accumulate intracellularly in osteoclasts. Simple bisphosphonates such as clodronate are incorporated into non-hydrolysable analogues of adenosine triphosphate, which induce osteoclast apoptosis. The considerably more potent nitrogen-containing bisphosphonates are not metabolised but potently inhibit farnesyl pyrophosphate (FPP) synthase, a key enzyme of the mevalonate pathway. This prevents the synthesis of isoprenoid lipids necessary for the post-translational prenylation of small GTPases, thereby disrupting the subcellular localisation and normal function of these essential signalling proteins. Inhibition of FPP synthase also results in the accumulation of the upstream metabolite isopentenyl diphosphate, which is incorporated into the toxic nucleotide metabolite ApppI. Together, these properties explain the ability of bisphosphonate drugs to inhibit bone resorption by disrupting osteoclast function and survival. These discoveries are also giving insights into some of the adverse effects of bisphosphonates, such as the acute phase reaction that is triggered by inhibition of FPP synthase in peripheral blood monocytes.
Collapse
|
40
|
Taylor A, Mules EH, Seabra MC, Helfrich MH, Rogers MJ, Coxon FP. Impaired prenylation of Rab GTPases in the gunmetal mouse causes defects in bone cell function. Small GTPases 2011; 2:131-142. [PMID: 21776414 PMCID: PMC3136943 DOI: 10.4161/sgtp.2.3.16488] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2011] [Accepted: 05/13/2011] [Indexed: 12/20/2022] Open
Abstract
Vesicular trafficking is crucial for bone resorption by osteoclasts, in particular for formation of the ruffled border membrane and for removal of the resultant bone degradation products by transcytosis. These processes are regulated by Rab family GTPases, whose activity is dependent on post-translational prenylation by Rab geranylgeranyl transferase (RGGT). Specific pharmacological inhibition of RGGT inhibits bone resorption in vitro and in vivo, illustrating the importance of Rab prenylation for osteoclast function. The gunmetal (gm/gm) mouse bears a mutation in the catalytic subunit of RGGT, causing a loss of 75% of the activity of this enzyme and hence hypoprenylation of several Rabs in melanocytes, platelets and cytotoxic T cells. We have now found that prenylation of several Rab proteins is also defective in gm/gm osteoclasts. Moreover, while osteoclast formation and cytoskeletal polarization occurs normally, gm/gm osteoclasts exhibit a substantial reduction in resorptive activity in vitro compared with osteoclasts from +/gm mice, which do not have a prenylation defect. Surprisingly, rather than the osteosclerosis that would be expected to result from defective osteoclast function in vivo, gm/gm mice exhibited a slightly lower bone mass than +/gm mice, indicating that defects in other cell types, such as osteoblasts, in which hypoprenylation of Rabs was also detected, may contribute to the phenotype. However, gm/gm mice were partially protected from ovariectomy-induced bone loss, suggesting that levels of Rab prenylation in gm/gm osteoclasts may be sufficient to maintain normal physiological levels of activity, but not pathological levels of bone resorption in vivo.
Collapse
Affiliation(s)
- Adam Taylor
- Musculoskeletal Programme; Division of Applied Medicine; Institute of Medical Sciences; University of Aberdeen; Foresterhill, Aberdeen UK
| | | | | | | | | | | |
Collapse
|
41
|
Sun S, Błażewska KM, Kashemirov BA, Roelofs AJ, Coxon FP, Rogers MJ, Ebetino FH, McKenna MJ, McKenna CE. Synthesis and characterization of novel fluorescent nitrogen-containing bisphosphonate imaging probes for bone active drugs. PHOSPHORUS SULFUR 2011; 186:970-971. [PMID: 21894242 DOI: 10.1080/10426507.2010.526674] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Progress in the synthesis of novel fluorescent conjugates of N-heterocyclic bisphosphonate drugs and related analogues, together with some recent applications of these compounds as imaging probes, are briefly discussed.
Collapse
Affiliation(s)
- Shuting Sun
- Department of Chemistry, University of Southern California, Los Angeles, CA, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Roelofs AJ, Thompson K, Ebetino FH, Rogers MJ, Coxon FP. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des 2011; 16:2950-60. [PMID: 20722616 DOI: 10.2174/138161210793563635] [Citation(s) in RCA: 136] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2010] [Accepted: 07/12/2010] [Indexed: 11/22/2022]
Abstract
Bisphosphonates are widely used in the treatment of diseases involving excessive bone resorption, such as osteoporosis, cancer-associated bone disease, and Paget's disease of bone. They target to the skeleton due to their calcium-chelating properties, where they primarily act by inhibiting osteoclast-mediated bone resorption. The simple bisphosphonates, clodronate, etidronate and tiludronate, are intracellularly metabolised to cytotoxic ATP analogues, while the more potent, nitrogen-containing bisphosphonates act by inhibiting the enzyme FPP synthase, thereby preventing the prenylation of small GTPases that are necessary for the normal function and survival of osteoclasts. In recent years, these concepts have been refined, with an increased understanding of the exact mode of inhibition of FPP synthase and the consequences of inhibiting this enzyme. Recent studies further suggest that the R2 side chain, as well as determining the potency for inhibiting the target enzyme FPP synthase, also influences bone mineral binding, which may influence distribution within bone and duration of action. While bisphosphonates primarily affect the function of resorbing osteoclasts, it is becoming increasingly clear that bisphosphonates may also target the osteocyte network and prevent osteocyte apoptosis, which could contribute to their anti-fracture effects. Furthermore, increasing evidence implicates monocytes and macrophages as direct targets of bisphosphonate action, which may explain the acute phase response and the anti-tumour activity in certain animal models. Bone mineral affinity is likely to influence the extent of any such effects of these agents on non-osteoclast cells. While alternative anti-resorptive therapeutics are becoming available for clinical use, bisphosphonates currently remain the principle drugs used to treat excessive bone resorption.
Collapse
Affiliation(s)
- A J Roelofs
- Bone & Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, United Kingdom.
| | | | | | | | | |
Collapse
|
43
|
Ford LA, Roelofs AJ, Anavi-Goffer S, Mowat L, Simpson DG, Irving AJ, Rogers MJ, Rajnicek AM, Ross RA. A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol 2010; 160:762-71. [PMID: 20590578 DOI: 10.1111/j.1476-5381.2010.00743.x] [Citation(s) in RCA: 115] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND AND PURPOSE Increased circulating levels of L-alpha-lysophosphatidylinositol (LPI) are associated with cancer and LPI is a potent, ligand for the G-protein-coupled receptor GPR55. Here we have assessed the modulation of breast cancer cell migration, orientation and polarization by LPI and GPR55. EXPERIMENTAL APPROACH Quantitative RT-PCR was used to measure GPR55 expression in breast cancer cell lines. Cell migration and invasion were measured using a Boyden chamber chemotaxis assay and Cultrex invasion assay, respectively. Cell polarization and orientation in response to the microenvironment were measured using slides containing nanometric grooves. KEY RESULTS GPR55 expression was detected in the highly metastatic MDA-MB-231 breast cancer cell line. In these cells, LPI stimulated binding of [(35)S]GTPgammaS to cell membranes (pEC(50) 6.47 +/- 0.45) and significantly enhanced cell chemotaxis towards serum. MCF-7 cells expressed low levels of GPR55 and did not migrate or invade towards serum factors. When GPR55 was over-expressed in MCF-7 cells, serum induced a robust migratory and invasive response, which was further enhanced by LPI and prevented by siRNA to GPR55. The physical microenvironment has been identified as a key factor in determining breast tumour cell metastatic fate. LPI endowed MDA-MB-231 cells with the capacity to detect shallow (40 nm deep) grooved slides and induced marked cancer cell polarization on both flat and grooved surfaces. CONCLUSIONS AND IMPLICATIONS LPI and GPR55 play a role in the modulation of migration, orientation and polarization of breast cancer cells in response to the tumour microenvironment.
Collapse
Affiliation(s)
- Lesley A Ford
- School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Abstract
The accuracy of protein biosynthesis rests on the high fidelity with which aminoacyl-tRNA synthetases discriminate between tRNAs. Correct aminoacylation depends not only on identity elements (nucleotides in certain positions) in tRNA (1), but also on competition between different synthetases for a given tRNA (2). Here we describe in vivo and in vitro experiments which demonstrate how variations in the levels of synthetases and tRNA affect the accuracy of aminoacylation. We show in vivo that concurrent overexpression of Escherichia coli tyrosyl-tRNA synthetase abolishes misacylation of supF tRNA(Tyr) with glutamine in vivo by overproduced glutaminyl-tRNA synthetase. In an in vitro competition assay, we have confirmed that the overproduction mischarging phenomenon observed in vivo is due to competition between the synthetases at the level of aminoacylation. Likewise, we have been able to examine the role competition plays in the identity of a non-suppressor tRNA of ambiguous identity, tRNA(Glu). Finally, with this assay, we show that the identity of a tRNA and the accuracy with which it is recognized depend on the relative affinities of the synthetases for the tRNA. The in vitro competition assay represents a general method of obtaining qualitative information on tRNA identity in a competitive environment (usually only found in vivo) during a defined step in protein biosynthesis, aminoacylation. In addition, we show that the discriminator base (position 73) and the first base of the anticodon are important for recognition by E. coli tyrosyl-tRNA synthetase.
Collapse
Affiliation(s)
- J M Sherman
- Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06511, USA
| | | | | |
Collapse
|
45
|
McKenna CE, Kashemirov BA, Błazewska KM, Mallard-Favier I, Stewart CA, Rojas J, Lundy MW, Ebetino FH, Baron RA, Dunford JE, Kirsten ML, Seabra MC, Bala JL, Marma MS, Rogers MJ, Coxon FP. Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid. J Med Chem 2010; 53:3454-64. [PMID: 20394422 DOI: 10.1021/jm900232u] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
3-(3-Pyridyl)-2-hydroxy-2-phosphonopropanoic acid (3-PEHPC, 1) is a phosphonocarboxylate (PC) analogue of 2-(3-pyridyl)-1-hydroxyethylidenebis(phosphonic acid) (risedronic acid, 2), an osteoporosis drug that decreases bone resorption by inhibiting farnesyl pyrophosphate synthase (FPPS) in osteoclasts, preventing protein prenylation. 1 has lower bone affinity than 2 and weakly inhibits Rab geranylgeranyl transferase (RGGT), selectively preventing prenylation of Rab GTPases. We report here the synthesis and biological studies of 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid (3-IPEHPC, 3), the PC analogue of minodronic acid 4. Like 1, 3 selectively inhibited Rab11 vs. Rap 1A prenylation in J774 cells, and decreased cell viability, but was 33-60x more active in these assays. After resolving 3 by chiral HPLC (>98% ee), we found that (+)-3-E1 was much more potent than (-)-3-E2 in an isolated RGGT inhibition assay, approximately 17x more potent (LED 3 microM) than (-)-3-E2 in inhibiting Rab prenylation in J774 cells and >26x more active in the cell viability assay. The enantiomers of 1 exhibited a 4-fold or smaller potency difference in the RGGT and prenylation inhibition assays.
Collapse
Affiliation(s)
- Charles E McKenna
- Department of Chemistry, University of Southern California, Los Angeles, California 90089-0744, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Robb TM, Rogers MJ, Woodward SS, Wong SS, Witten ML. In vitro time- and dose-effect response of JP-8 and S-8 jet fuel on alveolar type II epithelial cells of rats. Toxicol Ind Health 2010; 26:367-74. [DOI: 10.1177/0748233710370033] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
This study was designed to characterize and compare the effects of jet propellant-8 (JP-8) fuel and synthetic-8 (S-8) on cell viability and nitric oxide synthesis in cultured alveolar type II epithelial cells of rats. Exposure times varied from 0.25, 0.5, 1, and 6 hours at the following concentrations of jet fuel: 0.0, 0.1, 0.4, and 2.0 µg/mL. Data indicate that JP-8 presents a gradual decline in cell viability and steady elevation in nitric oxide release as exposure concentrations increase. At a 2.0 µg/mL concentration of JP-8, nearly all of the cells are not viable. Moreover, S-8 exposure to rat type II lung cells demonstrated an abrupt fall in percentage cell viability and increases in nitric oxide measurement, particularly after the 2.0 µg/mL was reached at 1 and 6 hours. At 0.0, 0.2, and 0.4 µg/mL concentrations of S-8, percentage viability was sustained at steady concentrations. The results suggest different epithelial toxicity and mechanistic effects of S-8 and JP-8, providing further insight concerning the impairment imposed at specific levels of lung function and pathology induced by the different fuels.
Collapse
Affiliation(s)
- Tiffany M Robb
- Department of Pediatrics and Southwest Environmental Health Sciences Center, The University of Arizona, Tucson, Arizona, USA
| | - Michael J Rogers
- Department of Pediatrics and Southwest Environmental Health Sciences Center, The University of Arizona, Tucson, Arizona, USA
| | - Suann S Woodward
- Department of Pediatrics and Southwest Environmental Health Sciences Center, The University of Arizona, Tucson, Arizona, USA
| | - Simon S Wong
- Department of Pediatrics and Southwest Environmental Health Sciences Center, The University of Arizona, Tucson, Arizona, USA,
| | - Mark L Witten
- Department of Pediatrics and Southwest Environmental Health Sciences Center, The University of Arizona, Tucson, Arizona, USA
| |
Collapse
|
47
|
Guenther A, Gordon S, Tiemann M, Burger R, Bakker F, Green JR, Baum W, Roelofs AJ, Rogers MJ, Gramatzki M. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 2009; 126:239-46. [PMID: 19621390 DOI: 10.1002/ijc.24758] [Citation(s) in RCA: 106] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Nitrogen-containing bisphosphonates (N-BPs) are effective antiosteolytic agents in patients with multiple myeloma. Preclinical studies have also demonstrated that these agents have direct antitumor effects in vitro and can reduce tumor burden in a variety of animal models, although it is not clear whether such effects are caused by direct actions on tumor cells or by inhibition of bone resorption. N-BPs prevent bone destruction in myeloma by inhibiting the enzyme farnesyl pyrophosphate synthase in osteoclasts, thereby preventing the prenylation of small GTPase signaling proteins. In this study, utilizing a plasmacytoma xenograft model without complicating skeletal lesions, treatment with zoledronic acid (ZOL) led to significant prolongation of survival in severe combined immunodeficiency mice inoculated with human INA-6 plasma cells. Following treatment with a clinically relevant dose of ZOL, histological analysis of INA-6 tumors from the peritoneal cavity revealed extensive areas of apoptosis associated with poly (ADP-ribose) polymerase cleavage. Furthermore, Western blot analysis of tumor homogenates demonstrated the accumulation of unprenylated Rap1A, indicative of the uptake of ZOL by nonskeletal tumors and inhibition of farnesyl pyrophosphate synthase. These studies provide, for the first time, clear evidence that N-BPs have direct antitumor effects in plasma cell tumors in vivo and this is executed by a molecular mechanism similar to that observed in osteoclasts.
Collapse
Affiliation(s)
- Andreas Guenther
- Division of Stem Cell Transplantion and Immunotherapy, 2nd Department of Medicine, University of Kiel, Kiel, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Whyte LS, Ryberg E, Sims NA, Ridge SA, Mackie K, Greasley PJ, Ross RA, Rogers MJ. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A 2009; 106:16511-6. [PMID: 19805329 PMCID: PMC2737440 DOI: 10.1073/pnas.0902743106] [Citation(s) in RCA: 234] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2009] [Indexed: 11/18/2022] Open
Abstract
GPR55 is a G protein-coupled receptor recently shown to be activated by certain cannabinoids and by lysophosphatidylinositol (LPI). However, the physiological role of GPR55 remains unknown. Given the recent finding that the cannabinoid receptors CB(1) and CB(2) affect bone metabolism, we examined the role of GPR55 in bone biology. GPR55 was expressed in human and mouse osteoclasts and osteoblasts; expression was higher in human osteoclasts than in macrophage progenitors. Although the GPR55 agonists O-1602 and LPI inhibited mouse osteoclast formation in vitro, these ligands stimulated mouse and human osteoclast polarization and resorption in vitro and caused activation of Rho and ERK1/2. These stimulatory effects on osteoclast function were attenuated in osteoclasts generated from GPR55(-/-) macrophages and by the GPR55 antagonist cannabidiol (CBD). Furthermore, treatment of mice with this non-psychoactive constituent of cannabis significantly reduced bone resorption in vivo. Consistent with the ability of GPR55 to suppress osteoclast formation but stimulate osteoclast function, histomorphometric and microcomputed tomographic analysis of the long bones from male GPR55(-/-) mice revealed increased numbers of morphologically inactive osteoclasts but a significant increase in the volume and thickness of trabecular bone and the presence of unresorbed cartilage. These data reveal a role of GPR55 in bone physiology by regulating osteoclast number and function. In addition, this study also brings to light an effect of both the endogenous ligand, LPI, on osteoclasts and of the cannabis constituent, CBD, on osteoclasts and bone turnover in vivo.
Collapse
MESH Headings
- Animals
- Animals, Newborn
- Bone Density
- Bone Resorption/prevention & control
- Bone and Bones/cytology
- Bone and Bones/metabolism
- Cannabidiol/pharmacology
- Cell Line, Tumor
- Cells, Cultured
- Dose-Response Relationship, Drug
- Female
- Fluorescent Antibody Technique
- Humans
- Lysophospholipids/pharmacology
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Osteoblasts/cytology
- Osteoblasts/drug effects
- Osteoblasts/metabolism
- Osteoclasts/cytology
- Osteoclasts/drug effects
- Osteoclasts/metabolism
- Osteogenesis/drug effects
- Receptors, Cannabinoid/genetics
- Receptors, Cannabinoid/metabolism
- Receptors, G-Protein-Coupled/genetics
- Receptors, G-Protein-Coupled/metabolism
- Reverse Transcriptase Polymerase Chain Reaction
Collapse
Affiliation(s)
- Lauren S. Whyte
- Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, United Kingdom
| | | | | | - Susan A. Ridge
- Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, United Kingdom
| | - Ken Mackie
- Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN 47401
| | | | - Ruth A. Ross
- Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, United Kingdom
| | - Michael J. Rogers
- Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, United Kingdom
| |
Collapse
|
49
|
Hirbe AC, Roelofs AJ, Floyd DH, Deng H, Becker SN, Lanigan LG, Apicelli AJ, Xu Z, Prior JL, Eagleton MC, Piwnica-Worms D, Rogers MJ, Weilbaecher K. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone 2009; 44:908-16. [PMID: 19442620 PMCID: PMC2782613 DOI: 10.1016/j.bone.2009.01.010] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/09/2008] [Revised: 10/16/2008] [Accepted: 01/06/2009] [Indexed: 01/01/2023]
Abstract
Bisphosphonates (BPs), bone targeted drugs that disrupt osteoclast function, are routinely used to treat complications of bone metastasis. Studies in preclinical models of cancer have shown that BPs reduce skeletal tumor burden and increase survival. Similarly, we observed in the present study that administration of the Nitrogen-containing BP (N-BP), zoledronic acid (ZA) to osteolytic tumor-bearing Tax+ mice beginning at 6 months of age led to resolution of radiographic skeletal lesions. N-BPs inhibit farnesyl diphosphate (FPP) synthase, thereby inhibiting protein prenylation and causing cellular toxicity. We found that ZA decreased Tax+ tumor and B16 melanoma viability and caused the accumulation of unprenylated Rap1a proteins in vitro. However, it is presently unclear whether N-BPs exert anti-tumor effects in bone independent of inhibition of osteoclast (OC) function in vivo. Therefore, we evaluated the impact of treatment with ZA on B16 melanoma bone tumor burden in irradiated mice transplanted with splenic cells from src(-/-) mice, which have non-functioning OCs. OC-defective mice treated with ZA demonstrated a significant 88% decrease in tumor growth in bone compared to vehicle-treated OC-defective mice. These data support an osteoclast-independent role for N-BP therapy in bone metastasis.
Collapse
Affiliation(s)
- Angela C. Hirbe
- Department of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, MO, 63110
| | - Anke J. Roelofs
- Bone and Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD Scotland
| | - Desiree H. Floyd
- Department of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, MO, 63110
| | - Hongju Deng
- Department of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, MO, 63110
| | - Stephanie N. Becker
- Department of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, MO, 63110
| | - Lisa G. Lanigan
- Department of Veterinary Biosciences, College of Veterinary Medicine, Ohio State University, Columbus, OH
| | - Anthony J. Apicelli
- Department of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, MO, 63110
| | - Zhiqiang Xu
- Department of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, MO, 63110
| | - Julie L. Prior
- Molecular Imaging Center, Department of Radiology, Washington University School of Medicine, St. Louis, MO, 63110
| | - Mark C. Eagleton
- Department of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, MO, 63110
| | - David Piwnica-Worms
- Molecular Imaging Center, Department of Radiology, Washington University School of Medicine, St. Louis, MO, 63110
| | - Michael J. Rogers
- Bone and Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD Scotland
| | - Katherine Weilbaecher
- Department of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, MO, 63110
| |
Collapse
|
50
|
Sutherland KA, Rogers HL, Tosh D, Rogers MJ. RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro. Arthritis Res Ther 2009; 11:R58. [PMID: 19405951 PMCID: PMC2688211 DOI: 10.1186/ar2681] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2008] [Revised: 04/08/2009] [Accepted: 04/30/2009] [Indexed: 01/11/2023] Open
Abstract
INTRODUCTION Bisphosphonates are the most widely used class of drug for inhibiting osteoclast-mediated bone loss, but their effectiveness at preventing joint destruction in rheumatoid arthritis has generally been disappointing. We examined whether the ability of bisphosphonates to induce osteoclast apoptosis and inhibit bone resorption in vitro is influenced by the cytokine receptor activator of nuclear factor-kappa B ligand (RANKL), an important mediator of inflammation-induced bone loss. METHODS Rabbit osteoclasts were treated with the bisphosphonates clodronate or alendronate for up to 48 hours in the absence or presence of RANKL. Changes in cell morphology and induction of apoptosis were examined by scanning electron microscopy, whilst resorptive activity was determined by measuring the area of resorption cavities. Changes in the level of anti-apoptotic proteins, including Mcl-1, Bcl-2, and Bcl-x>L, were determined in rabbit osteoclasts and in cytokine-starved mouse osteoclasts by Western blotting. RESULTS RANKL significantly attenuated the ability of both clodronate and alendronate to induce osteoclast apoptosis and inhibit bone resorption. Treatment of rabbit osteoclasts with RANKL was associated with an increase in the anti-apoptotic protein Mcl-1 but not Bcl-2. A role for Mcl-1 in osteoclast survival was suggested using osteoclasts generated from mouse bone marrow macrophages in the presence of RANKL + macrophage colony-stimulating factor (M-CSF) since cytokine deprivation of mouse osteoclasts caused a rapid loss of Mcl-1 (but not Bcl-2 or Bcl-xL), which preceded the biochemical and morphological changes associated with apoptosis. Loss of Mcl-1 from mouse osteoclasts could be prevented by factors known to promote osteoclast survival (RANKL, M-CSF, tumour necrosis factor-alpha [TNF-alpha], or lipopolysaccharide [LPS]). CONCLUSIONS RANKL protects osteoclasts from the apoptosis-inducing and anti-resorptive effects of bisphosphonates in vitro. The ability of RANKL (and other pro-inflammatory factors such as TNF-alpha and LPS) to increase the level of Mcl-1 in osteoclasts may explain the lack of effectiveness of some bisphosphonates in preventing inflammation-induced bone loss.
Collapse
Affiliation(s)
- Karen A Sutherland
- Bone & Musculoskeletal Research Programme, School of Medicine & Dentistry, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK
| | - Helena L Rogers
- Bone & Musculoskeletal Research Programme, School of Medicine & Dentistry, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK
| | - Denise Tosh
- Bone & Musculoskeletal Research Programme, School of Medicine & Dentistry, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK
| | - Michael J Rogers
- Bone & Musculoskeletal Research Programme, School of Medicine & Dentistry, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK
| |
Collapse
|